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Abstract
Tendons are a unique orthopaedic tissue that rely on a highly ordered tissue matrix for proper function.
Tendon disease degrades this matrix order, causing deviations in resident cell behavior that result in
decreased tissue function. Treatments for tendon disease remain ineffective due to a knowledge gap in
the factors most vital for maintaining tendon health. Many matrix molecules help regulate tendon growth
and maintenance, including biglycan and collagen VI. These molecules are attributed to the pericellular
matrix, a critical matrix structure that preserves cellular health across multiple contexts. The role of the
PCM, and how interactions between biglycan and collagen VI govern tendon health, however, remain
unknown. This dissertation defined the coordinate roles of biglycan and collagen VI and determined that
while both molecules are key for tendon health, collagen VI is a more robust regulator, and that biglycan
and collagen VI do not play additive roles in tendon. This work sought to further refine biglycan’s
regulatory mechanism in tendon by leveraging a unique model system of distinct tendon matrix
environments – “wrap-around” tendons. In addition to the characteristic, aligned tendon matrix, wraparound tendons contain a matrix that more closely mimics fibrocartilage. This work analyzed the effect of
biglycan knockout across these distinct tissue contexts to determine the molecular mechanism by which
biglycan regulates tendon function. In doing so, we mapped the postnatal development of regional tendon
properties for the first time in mice. Results from this work demonstrate that while biglycan may regulated
tendon function through the PCM, this mechanism is likely independent of collagen VI interactions.
Instead, biglycan may regulate tendon properties by directly organizing the collagen matrix. Overall, this
work provides unique insight into the role of biglycan across distinct tendon matrix environments and lays
the foundation for future work that may identify the factors most essential for preserving tendon health.
Such knowledge is critical for the prevention and treatment of tendon disease.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Bioengineering

First Advisor
Louis J. Soslowsky

Keywords
Biglycan, Biology, Extracellular Matrix, Pericellular Matrix, Tendon

This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/5500

BIGLYCAN REGULATION OF REGIONAL TENDON DEVELOPMENT
VIA THE PERICELLULAR MATRIX
Ryan Jonathan Leiphart
A DISSERTATION
in
Bioengineering
Presented to the Faculties of the University of Pennsylvania
in
Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2022

Supervisor of Dissertation

Graduate Group Chairperson

_____________________

_______________________

Louis J. Soslowsky, PhD

Yale Cohen, PhD

Fairhill Professor of Orthopaedic Surgery

Professor of Bioengineering

Dissertation Committee
Rebecca G. Wells, MD (Committee Chair)
Professor of Medicine
Nathaniel A. Dyment, PhD
Assistant Professor of Orthopaedic Surgery
Marian F. Young, PhD
Deputy Scientific Director, National Institute of Dental and Craniofacial Research

BIGLYCAN REGULATION OF REGIONAL TENDON DEVELOPMENT
VIA THE PERICELLULAR MATRIX
COPYRIGHT
2022
Ryan Jonathan Leiphart

This dissertation is dedicated to my family, friends, and to Olivia, without whom I would not have
the strength, energy, nor drive to achieve even the smallest of feats

iii

ACKNOWLEDGMENTS
They say it takes a village to raise a child. In that same vein, no person earns their PhD
alone. To achieve such a degree requires a Herculean team effort, and there are many people
who deserve thanks for helping me arrive at this destination.
I would first like to thank my advisor, Dr. Lou Soslowsky. From the moment I interviewed
with Lou, I knew we were aligned in scientific philosophy. Through that philosophy and his
mentorship, Lou provided me the reins for my education. I was allowed to explore, to learn, and to
grow into the scientist I am today, and I have Lou to thank for that. I am grateful for every lesson
learned under Lou’s advisorship.
My committee members also deserve thanks for contributing to my scientific maturation.
Dr. Becky Wells, my committee chair, taught my favorite class at Penn – The Extracellular Matrix.
So much of Becky’s teaching inspired this dissertation work, and I have the upmost respect for
how Becky has contributed to and improved this project. Dr. Marian Young also provided valuable
mentorship. Through collaborations and life conversations, Marian imparted unique insight that
helped me survive the final stages of thesis work. And I would certainly not be the scientist today
without Dr. Nat Dyment. It was serendipitous that our Penn careers coincided as they did,
because Nat taught me everything I know about biological assays. Through Nat’s mentorship, I
was able to expand the scope of this dissertation in a manner impossible without him. As an
amazing mentor, colleague, and friend, I know that Nat will continue to achieve excellence with all
that he does.
While mentorship and advising is necessary for project management, this work would not
be successful without the nitty gritty technical help that many provided. Nat and Dr. Xi Jiang were
instrumental in teaching me gene expression techniques. Xi, Catherine Bautista, and Mary-Kate
Evans all provided essential guidance in learning the histological techniques presented here. I am
so grateful for their kind answers to all my interruptive questions. Dr. Jeremy Eekhoff, Chet
Friday, Ashley Fung, and Mike DiStefano contributed vital aid in the final hours of mechanical
testing and analysis. I am not sure how I would’ve managed without you. Finally, a huge shout

iv

out to the “Mouse Queen” of the Soslowsky Lab, Steph Weiss. I had no idea about the difficulty of
mouse breeding. Now, I have more respect for Steph than ever before and am grateful I will no
longer be on pup watch.
In addition to direct, technical support, I received an incredible amount of emotional
support during my journey at Penn. All the Soslowsky and McKay Lab coworkers with whom I’ve
worked alongside provided such help. Specific thanks to the Soslowsky graduate students – Drs.
Ben Freedman and Cori Riggin, Zak Beach, Joey Newton, Ashley Fung, Thomas Leahy, Mike
DiStefano, and Maggie Tamburro – for always being there to vent and to work through the daily
struggles of lab work. Dr. Brittany Taylor and Ashley Rodriguez also provided invaluable
companionship, of which I am still appreciative today. While the lessons learned through Drs.
Snehal Shetye and Julianne Huegel were not always well-received, I am grateful for their
mentorship as well. I am so lucky to have worked with those of the greater McKay community.
This group taught and pushed me every day. As they say, iron sharpens iron. The administrative
McKay staff were also instrumental for my growth, and specific thanks to Kristine Zagrocki, Susan
Dinella, and Donna Seravello for their unwavering friendship.
I have many mentors outside of the lab space that imparted priceless lessons through my
years. Dr. David Sarmiento taught me, through wrestling, mental toughness and what it takes to
achieve the highest forms of success. Dr. Sanjay Konagurthu took a chance on me with an
industry internship, an experience that propelled me to the achievements I have today. Mary Beck
taught me how to instruct but more importantly how to care for someone. Dr. Peter Norton
unlocked my previously undiscovered ability to write. Dr. LeAnn Dourte provided such impactful
lessons for navigating graduate school life, and I enjoyed all the lab reprieves in visiting her office.
Professional relationships alone are not enough to survive graduate school, and I am
lucky to have some amazing friendships that let me live a full life during this time. Penn friends
such as Drs. Jon Galarraga and Andrei Georgescu, Zak Beach, Joey Newton, Eric Dai, Drs.
Sonia Kartha, Rhea Chitalia, and Divya Jain, Rebecca Chung, and Ward Sandler were always
willing to share adventures and escape the monotony of labwork. With this group, and with many

v

others, I was able to take my mind off work, even for fleeting moments. With the stress of
graduate school, this may be the ultimate gift. My UVa crew was also essential for maintaining my
sanity. People like Ossman Cossio, Nathan Thillairajah, Jake Sperling, Maria Cosentino, Cole
Schafer, George Luo, and Austin Farquhar reminded me to never take things too seriously and
that everything tends to fall in the right place. Without their perspective I would still be lost in life.
My hometown friends, specifically Connor Barrett and Fintan Doyle, have also been instrumental
in shaping who I am today. While I have not shared the most memories with them recently, being
on the other coast, I cannot wait for future adventures with those two.
In addition to amazing friendship, I have such an incredible family to thank for their
support and love during this time. Being local to Philly, I got to know the Pappas’ much better
during graduate school. As my only uncle, aunt, and cousins, the ability to connect with them was
an immense support that I desperately needed. My brothers, Patrick and Grant, have always
played an immeasurable role in my life. While we had grown distant as I pursued education on
the east coast, we are now as close as ever, and I am so grateful for that. I cannot wait to see all
that they accomplish with their talent and dedication. My parents, Melissa and Shane, have given
me everything I could ask for in an upbringing. They allowed me to pursue any avenue I enjoyed
and never pressured me to be anyone but myself. I look forward to showing my appreciation for
them moving forward, as I know my pimply, teenage self did not effectively communicate such.
While no surviving grandparents can witness me earn this PhD, I know that Yiayia, Papou, and
PopPop are watching, smiling, and are proud.
Finally, the love of my life, Olivia Snow. To say I was lucky to stumble into your love
would be an understatement. I was lost when I met you, and since then, you have provided so
much purpose, energy, and life to my every day. We have both made immense sacrifices to
preserve our partnership, but I would not have it any other way. You are my guiding light, my
esprit de corps, my joie de vivre. I cannot wait to see everything we achieve and experience
together. As crazy and magical as the past three years have been, the next decades will be that
much more.

vi

ABSTRACT
BIGLYCAN REGULATION OF REGIONAL TENDON DEVELOPMENT VIA THE
PERICELLULAR MATRIX
Ryan Jonathan Leiphart
Louis J. Soslowsky
Tendons are a unique orthopaedic tissue that rely on a highly ordered tissue matrix for
proper function. Tendon disease degrades this matrix order, causing deviations in resident cell
behavior that result in decreased tissue function. Treatments for tendon disease remain
ineffective due to a knowledge gap in the factors most vital for maintaining tendon health. Many
matrix molecules help regulate tendon growth and maintenance, including biglycan and collagen
VI. These molecules are attributed to the pericellular matrix, a critical matrix structure that
preserves cellular health across multiple contexts. The role of the PCM, and how interactions
between biglycan and collagen VI govern tendon health, however, remain unknown. This
dissertation defined the coordinate roles of biglycan and collagen VI and determined that while
both molecules are key for tendon health, collagen VI is a more robust regulator, and that
biglycan and collagen VI do not play additive roles in tendon. This work sought to further refine
biglycan’s regulatory mechanism in tendon by leveraging a unique model system of distinct
tendon matrix environments – “wrap-around” tendons. In addition to the characteristic, aligned
tendon matrix, wrap-around tendons contain a matrix that more closely mimics fibrocartilage. This
work analyzed the effect of biglycan knockout across these distinct tissue contexts to determine
the molecular mechanism by which biglycan regulates tendon function. In doing so, we mapped
the postnatal development of regional tendon properties for the first time in mice. Results from
this work demonstrate that while biglycan may regulated tendon function through the PCM, this
mechanism is likely independent of collagen VI interactions. Instead, biglycan may regulate
tendon properties by directly organizing the collagen matrix. Overall, this work provides unique
insight into the role of biglycan across distinct tendon matrix environments and lays the
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foundation for future work that may identify the factors most essential for preserving tendon
health. Such knowledge is critical for the prevention and treatment of tendon disease.
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CHAPTER 1: INTRODUCTION
Tendon is an essential musculoskeletal tissue that relies on a uniquely ordered
matrix to function. The tissue is prone to degeneration in which this matrix order is lost,
yet treatments for this degeneration remain elusive. Tendon homeostasis is driven by
coordination of extracellular matrix molecules and structures, including biglycan and the
pericellular matrix. Despite interactions between biglycan and the pericellular matrix that
likely maintain tendon health, the mechanisms by which these matrix components
regulate tendon are unknown. “Wrap-around” tendons contain two distinct matrix
phenotypes in which the tendon-regulating role of matrix molecules can be studied. This
work seeks to define biglycan and pericellular matrix regulatory mechanisms, including
their involvement in driving these unique wrap-around tendon regional properties.
Understanding these mechanisms would inform the factors and stimuli most critical for
tendon homeostasis and disease prevention.
1.1. Tendon as a Tissue – Function, Structure, and Disease
Tendon is a musculoskeletal tissue that is necessary for movement and stability.
Tendon serves a tensional role connecting muscle and bone, thereby transmitting
muscle contractile forces to the skeletal system. There is estimated to be up to 4,000
tendons in the human body,1 each having a specific role within muscle force
transmission. Some tendons, like the Achilles tendon, impart large forces and displace
limbs for locomotion. Other tendons, such as flexor and diaphragmatic tendons, provide
skeletal stability for fine motor control and balance. Like the strings of a marionette,
tendons are indispensable for body kinematics.
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To provide its essential role in muscle force transmission, tendon relies on a
highly ordered and hierarchical tissue structure (Figure 1-1). The primary component of
tendon is collagen I, a fibrous protein that resists tensile forces along its long axis.2–5 In
tendon, collagen I is longitudinally organized into nanometer-scale bundles called fibrils.
These fibrils aggregate into collagen fibers, a larger subunit of tendon on the order of
several microns. These fibers combine to form tendon fascicles, which are held together
by a connective tissue matrix to form the whole tendon tissue. This hierarchical structure
ensures that forces are uniformly spread over the entire tissue cross-section, thereby
minimizing stress concentrations and force imbalances.

Figure 1-1. Tendon structure is hierarchically organized. The primary
component of tendon, collagen I, aggregates in a highly ordered fashion
to form tendon tissue. Collagen I molecules form fibrils, which scale to
fibers and fascicles, which are bundled together to comprise the whole
tendon. Reprinted with permission.2

Tendon structure also contains a dynamic order to properly respond to and resist
muscle forces for efficient transmission to the bone. In a resting, non-tensioned state,
collagen fibers and fibrils display a wavy, crimp-like pattern.6–9 As muscle contracts and
tensions its associated tendon, this collagen crimp unwinds, aligns, and stretches
2

(Figure 1-2).7,10–13 During this initial stretching, the tendon is strained without much
resistance. Once the collagen fibrils and fibers are aligned, the tissue becomes much
more resistant to forces, resulting in minimal stretch per unit of force applied. This
transition from a compliant tissue to one of great strength allows for proper control of
bone kinetics while preserving tendon health. As further force and stress is applied to
tendon, bonds between collagen fibrils are broken, and the fibrils slide past one
another.14,15 This mechanism provides further protection to tendon. Excess forces
beyond this fibril sliding threshold may cause irreversible damage to the tendon matrix.

Figure 1-2. Tendon responds
dynamically to load. When exposed
to external loads, tendon initially
behaves as a compliant tissue with
high displacements per unit load. As
the applied load increases, collagen
fibrils uncrimp and realign. This
transition stiffens the tendon, resulting
in low displacements per unit load.
Once fibrils realign, they slide past
one another in response to additional
loads before permanent damage
arises. Reprinted with permission.13

Within the ordered and dynamic tendon matrix, tendon cells reside and preserve
tissue health. Tendon cells, or tenocytes, are considered a subset of fibroblastic cells
that produce and maintain the collagenous tendon matrix.3,16 Tenocytes are embedded
within collagen fibrils and assume an elongated, spindle-like morphology. As the tendon
develops and grows, the tissue transitions from a highly cellular environment to a matrix
dominant one.17 During early development, tenocytes are arranged in parallel linear
arrays.18–20 While these arrays are also present in mature tendons, tenocytes are more
3

dispersed throughout the tissue matrix.17 The combination of an aligned collagen matrix
with spindle-shaped tenocytes can be described as a healthy “tenogenic” environment.
In a tenogenic environment, tenocytes sense physiological forces and stimuli that
maintain their tissue-specific phenotype. Tenocytes in turn maintain their tenogenic
environment with proper matrix production and remodeling to ensure proper tissue
function.
While healthy tendons display tenogenic properties, the tissue is prone to
degeneration that reduces native “tenogenicity”. Tendon degeneration, or tendinopathy,
is a large clinical burden, with an estimated 10.52 cases per 1,000 person-years in lower
limbs alone.21 Tendinopathy is associated with a loss of tenogenic matrix properties.
Tendinopathic tendons contain a disorganized matrix with increased presence of noncollagenous matrix molecules (Figure 1-3).22–25 Tenocytes within these degenerated
tendons lose their spindle-like morphology and take on a rounded morphology that is
associated with native cartilage and fibrocartilage cells. These decreases in matrix and
cell tenogenicity result in inferior tissue properties, as degenerated tendons have
reduced mechanical resistance.26 This loss of tissue strength can lead to matrix damage
given the same applied forces, which may result in further degeneration or acute injury.
While the hallmarks of tendinopathy have been well-established, treatments for
tendinopathy, as well as its initiating causes, remain elusive. Understanding these
driving factors behind tendon degeneration would inform proper treatment and
prevention of tendon disease.

4
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Figure 1-3. Degenerated tendons display a disrupted matrix that corresponds with
decreased tissue function. While a healthy tendon matrix consists of spindle-shaped
tenocytes embedded within organized collagen bundles (A), degenerated tendons contain
rounded cell morphology and a disorganized matrix (B). This degenerated matrix results in
decreased tendon mechanical properties (C). (A) + (B)25 and (C)26 reprinted with permission.

1.2. The Extracellular Matrix - Overview and Interactions Within Tendon
The extracellular matrix (ECM) is an essential tissue compartment for the
function of nearly every organ. Encompassing all molecules and space outside of cells,
the ECM provides structural support and signaling cues for native cells.27–29 These cells
dynamically attach to ECM molecules, tugging and pulling to sense their mechanical
environment. The stiffness of the surrounding ECM is a large driver of cell fate, and cells
assume distinct lineages based on the mechanical cues that they sense.30–33 ECM
molecules also serve as a signaling hub by sequestering and presenting molecules that
trigger key cell signaling pathways.34,35 Through its extensive mechanical and molecular
properties, the ECM fuels cell behavior. This cell behavior may involve secretion of
5

further ECM molecules, creating a feedback loop between cells and their matrix
environment.36,37 Such feedback loops may maintain homeostasis, may attempt to
restore damaged tissue, or may result in further degeneration to the surrounding tissue.
Like most tissues, tendon is highly reliant on its ECM. As mentioned, collagen I is
a large component of the tendon ECM, making up ~80% of the tissue’s dry weight and
imparting most of the tissue’s mechanical strength. While in relatively lower abundance,
other key ECM molecules are present in tendon and fall into categories including
collagens, proteoglycans, and matricellular proteins (Figure 1-4).38–42 Despite their
proportions, these lower abundance matrix proteins (LAMPs) are essential for preserving
tenogenic properties. Molecules such as collagen V,43–46 collagen XI,47,48 decorin,49–51
and lumican52,53 tightly regulate the formation of collagen I fibrils, or fibrillogenesis. By
modulating collagen fibril size and shape, fibrillogenic LAMPs titrate tendon mechanical
properties to provide proper resistance to applied forces.48,54–60 Other LAMPs, such as

Figure 1-4. The tendon ECM
contains a diverse set of proteins.
Collagen I is the primary matrix
constituent of tendon. However, a
diverse group of proteins also
comprise the tendon ECM. Such
molecules include other collagens,
proteoglycans, and matricellular
proteins. Adapted with permission.42
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tenomodulin,61–63 serve as signal drivers for resident tenocytes and help maintain native
cell phenotypes. Whether through genetic mutations or experimental knockouts, tendons
deficient in these LAMPs contain disrupted collagen matrices and abnormal tenocyte
behavior. This diminished tenogenic environment results in decreased tissue properties
and function. While the importance of these LAMPs in tendon homeostasis have been
established, and while some mechanisms of regulation have been elucidated, there is
still a lack of understanding of the key matrix interactions within tendon and how these
interactions guide proper tenocyte behavior and tissue function. Defining these
interactions may unlock key applications to therapeutic modalities for the prevention and
treatment of tendon disorders.
1.3. Biglycan – Overview and Tendon Regulation
One LAMP that plays a key regulatory role is biglycan. Biglycan is a class I small,
leucine-rich proteoglycan (SLRP) that is comprised of a small (42kDa) core protein and
two glycosaminoglycan (GAG) chains.64,65 Through this structure, biglycan can bind to
and interact with several ECM proteins, including collagen I,66,67 collagen VI,68,69
aggrecan,70 etc. Biglycan can also sequester TGF-β, a key signaling molecule that
drives cell fate and behavior.71–73 Inflammatory pathways that involve Toll-like receptor
signaling are modulated by biglycan.74,75 By binding to and organizing ECM proteins and
by serving as a signaling hub, biglycan regulates many tissues and organs. Kidney,76,77
heart,78,79 bone,80,81 and muscle82,83 are all responsive and sensitive to biglycan
presence.
Given its role in muscle and bone, it is unsurprising that biglycan is a critical
regulator of tendon function. Biglycan expression peaks in tendon during early
development.84,85 With this developmental expression, it is thought that biglycan serves
as a key molecule in the tendon stem cell niche, thereby regulating tendon stem cell
7

behavior. This is evidenced by resident tenocytes losing tenogenic gene expression in
biglycan knockout mice86 and reciprocal increases in tenogenic expression and
differentiation with addition of biglycan protein to tenocyte culture.87 By regulating native
tenogenicity, biglycan aids in the formation of a healthy tendon matrix and drives tendon
function. Biglycan deficiency results in abnormal collagen fibril size in tendon.88–90 This
aberrant matrix in biglycan-deficient tendons leads to tendon-specific disruptions to
mechanical properties, including increased viscoelasticity,90,91 decreased modulus,90–92
max load,91 and max stress,92 and changes in collagen fiber realignment in response to
load.93 While biglycan’s importance during tendon development and in establishing
tenogenic properties has been elucidated, the specific matrix mechanism by which
biglycan regulation occurs remain elusive. There is clinical importance to understanding
this mechanism, as biglycan expression and matrix presence is increased in
tendinopathy.94–96 This implicates biglycan in the onset and progression of tendon
disease. Defining the regulatory mechanisms of biglycan in tendon would therefore
inform tendinopathy treatments.
1.4. The Pericellular Matrix - Overview, Compositional Interactions, and the
Unknown Role in Tendon
In addition to the role that single matrix molecules play in regulating tissue
properties, there are distinct matrix structures - comprised of several matrix molecules that play critical roles in establishing and maintaining native tissue. One example of
these structures is the pericellular matrix (PCM). As the name implies, the PCM is the
matrix that immediately surrounds cells. The PCM is therefore the main transducer of
mechanical forces to the cell, especially in musculoskeletal tissues such as cartilage and
fibrocartilage.97,98 The cellular proximity also contributes to the PCM’s role as a signaling
reservoir that presents key ligands to native cells. Due to these properties, the PCM is
8

essential for cell homeostasis and maintaining tissue health. Changes in PCM properties
are associated with the onset of diseases like osteoarthritis, further implicating the
specialized matrix in regulating tissue phenotype.99 In musculoskeletal contexts, where
tissues function in response to mechanical forces, it is critical to understand the role of
the PCM in maintaining tissue function.
Since the PCM is an amalgam of various matrix molecules, interactions between
these molecules guide proper PCM structure and function. The primary component of
the PCM is collagen VI. Collagen VI is a non-fibrillar collagen that forms a tetramer and
organizes into a hexagonal, mesh-like network in the extracellular space.100 This mesh
ultrastructure is also attributed to the PCM at large.101 While collagen VI can form this
mesh structure on its own, it is very inefficient at self-aggregating.102 Biglycan, however,
localizes to the PCM,103,104 is capable of binding to collagen VI,68 and has been shown to
efficiently organize collagen VI fibrils into a hexagonal network (Figure 1-5).102 Further,
biglycan binding to collagen VI serves as a “connecting bridge” to other ECM molecules
like collagen II and aggrecan.70 These results suggest that biglycan is a critical regulator

Figure 1-5. Biglycan organizes collagen VI into PCM-resembling structure. When
combined in vitro, biglycan and collagen VI spontaneously organize into a hexagonal
filament network. This network resembles the structure of cartilage and tendon PCM.
Adapted with permission.102
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of PCM structure. The impact of this structural role on the in vivo function of the PCM,
however, remains elusive.
While the PCM has been studied extensively in cartilage and fibrocartilage, there
is a dearth of research on the tendon PCM and its regulatory role. A tendon PCM has
been identified and isolated (Figure 1-6).105 While the cartilage and fibrocartilage PCM
encloses isolated cells, the tendon PCM contains several cells arranged in linear arrays.
Despite this difference, the tendon PCM ultrastructure resembles that of other tissues
and contains similar constituent molecules (collagen VI, versican, fibrillin-2, etc.).
Although collagen VI is known to be a critical tendon regulator106 and is implicated in
tendon injury,107 the mechanisms by which the tendon PCM influences cell
mechanosensation and resulting tissue health remains unknown. Given its key role in
other tissues, it is likely that PCM mechanisms are essential for tenogenic maintenance.
Understanding how these mechanisms regulate tenocyte biology, and the specific role of
biglycan within the PCM, likely reveal the factors most critical for maintaining tendon
function.

A

Figure 1-6. Tendon contains a
collagen VI rich PCM. Digested
tendons reveal a PCM structure
(red arrows) that encapsulates
tenocytes (white arrows) within
linear
arrays
(A).
The
ultrastructure of this PCM
resembles a hexagonal network
that is characteristic of collagen
VI aggregation (white arrows, B).
This network binds directly to the
cell plasma membrane (PM).
Adapted with permission.106

B
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1.5. Fibrocartilage in Tendon – A Distinct Matrix in Response to Distinct Loads
Although the PCM-centric mechanisms through which tenocytes sense forces
remain unknown, there are in situ instances of tenocytes responding to nonphysiological forces that result in distinct matrix environments. When tendons wrap
around joint spaces, such as flexor tendons spanning the wrist or ankle joints, the tissue
is exposed to off-axis, complex forces. These complex forces, including compression
from contact with the underlying bone through joint flexion, elicit a “non-tenogenic”
response from tenocytes. These ”compressed” regions display increased expression of
(fibro)cartilage matrix genes, such as Col2a1 and Acan.108,109 This non-tenogenic
expression results in a local matrix environment that more closely mimics that of
fibrocartilaginous tissue (Figure 1-7).110,111 In this fibrocartilaginous “wrap-around” region,

Figure 1-7. Tendon “wrap-around” regions contain a unique fibrocartilaginous matrix.
Tendons that span joints, such as the peroneus brevis (PB), contain distinct matrices in the
region that wraps around the joint. Regions of these tendons that experience tensile loads
appear like healthy, organized tendon (A). The wrap-around regions, however, display
“woven” collagen fiber (CF) architecture, and resident cells assume a rounded morphology
that mimics fibrochondrocytes. Adapted with permission.110
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resident cells assume a rounded morphology, and the surrounding matrix is less aligned
with increased presence of matrix proteoglycans. This distinct matrix is in direct
response to compressive forces, as further compression exacerbates the non-tenogenic
phenotype.112–115 This response to compression is more robust in wrap-around regions
compared to normal, “tensile” regions of tendon, suggesting that cells native to these
wrap-around regions are primed to produce this fibrocartilaginous matrix. The nontenogenic phenotype is reversible, however, as flexor tendons that are dislocated from
the joint (and therefore no longer exposed to joint loads) remodel and recede the
fibrocartilage matrix.116 The response of native tenocytes to non-physiological, complex
forces, and the plasticity of this response, reveals key aspects of tendon homeostasis in
response to forces. Understanding how tenocytes dynamically respond to in vivo loads
could unearth crucial paradigms in the treatment and prevention of tendon disease. The
molecules, signals, and stimuli that are most important to tenocyte load-sensitivity,
however, remain unknown.
Interestingly, biglycan is one of the matrix molecules that is most up-regulated in
fibrocartilage wrap-around regions of tendon.108,109,113,114 This may be expected given
biglycan’s role in cartilage.117 Considering the role of biglycan in regulating tendon
properties, biglycan’s localization to the PCM, and its increased presence in wraparound tendon regions, there is profuse evidence that biglycan plays a critical role in
tenocyte mechanosensation and homeostasis. This role may be a function of proper
PCM organization. However, the extent to which the PCM dictates tendon’s response to
altered in vivo loads remains unknown. This work seeks to define biglycan’s mechanistic
role in maintaining tenogenicity, and to delineate the PCM’s involvement in these
mechanisms. Such understanding would reveal the matrix stimuli most critical for tendon
health and function.
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1.6. Significance of Studies
1.6.1. Interactions between Biglycan and the Pericellular Matrix in Regulating Tendon
Properties
Given the role of biglycan in regulating tendon function,86,88–90 the role of the PCM
in dictating cell mechanosensation,97,98 and the known interactions of biglycan within the
PCM,102–104 it is likely that biglycan regulates tendon properties via the tendon PCM.
Biglycan and the tendon PCM are also implicated in tendon disease, further suggesting
an important role of this molecule and structure for tendon homeostasis.94–96,107 Despite
evidence that these molecules and structures are critical tendon regulators, little is
known about the mechanisms by which they define tendon tissue health. This work
delineates the roles of biglycan and of collagen VI, the primary PCM component, in
controlling tendon function. This work also defines how biglycan impacts the behavior of
tenocytes and the extent to which this regulation involves the PCM. In achieving these
objectives, this dissertation maps the postnatal development of regional tendon
properties, providing a unique model system for future studies on tendon
mechanosensitivity. Elucidating these cellular and mechanosensitive mechanisms
provides key insights into how tendons sense and adapt to mechanical cues. Such
understanding informs tendon treatment paradigms to help restore healthy tendon
loading and maintain tissue health.
1.6.2. Development of Novel Biglycan Knockout and Reporter Mouse Models
While biglycan’s role in tendon has been researched, prior studies used
conventional knockout mouse models in which biglycan is globally knocked out.86,88–93 A
global knockout will impact non-tendon tissues in which biglycan plays a regulatory role,
such as bone and muscle. Crosstalk between bone and muscle influence tendon
health.118,119 Confounding effects of biglycan knockout on neighboring tissues may lead
13

to effects on tendon properties that are unrelated to biglycan’s direct role in the tissue.
To avoid these off-target effects, this work employs a novel Scx- (scleraxis-) targeted
biglycan knockout mouse model. Scleraxis is the most robust tendon marker
available,120 thus a Scx-targeted biglycan knockout would ablate Bgn knockout with high
tissue-specificity. Results from this model therefore provide precise understanding of
biglycan’s tendon-specific regulatory role.
This work will merge a Scx-targeted biglycan knockout model with various GFP
reporter mouse lines. GFP reporter lines, such as the Scx-GFP line, allow for targeted
analysis on specific cell populations within the tissue of interest.121,122 This analysis
provides unique insights into the behavior of these different cell populations across
multiple contexts. Despite the power of GFP reporter lines, their use in the context of
matrix molecule knockout remains limited. Merging ECM knockout models with reporter
lines can uncover cell-specific mechanisms by which ECM molecules regulate cell
behavior, thereby improving working models of cell-ECM interactions. This work uses
Scx- and Col6a1-GFP reporter lines to understand the differential response to biglycan
knockout in tendon lineage and PCM-synthesizing cell populations, respectively. By
delineating the response of these cell populations to biglycan knockout, this work
provides understanding of which population is most sensitive to biglycan presence and
how this sensitivity impacts overall tissue function.
1.6.3. Leveraging Distinct Tendon Regions as a Model of Differential Loading
As mentioned, regions of tendon that wrap-around joints display a distinct matrix
environment from a normal, healthy tendon. These regions are a direct cause of
compressive and complex forces that are imparted on the tendon through joint flexion.
Research on these wrap-around regions provided insights into how tendon cells respond
to distinct mechanical cues. However, these regions have not been leveraged to define
14

how matrix molecules govern cell behavior across multiple loading environments. This
work analyzes the effect of biglycan knockout in the normal (“tensile”) and wrap-around
(“compressive”) regions of the FDL tendon. By comparing the responses of these two
regions to biglycan knockout, this work further refines the model of biglycan regulation
across multiple tendon contexts. This understanding is critical, as biglycan’s role in
tendon is likely dependent on the loading environment.
1.7. Specific Aims
The overall goal of this work was to delineate the role of biglycan and the tendon
PCM in dictating tendon properties, to define the role of biglycan in regulating distinct
tendon regions through development, and to determine the extent to which this
regulation involves the tendon PCM. By using novel mouse models and leveraging a
unique tendon model system, this work provides holistic understanding of biglycan’s
regulatory mechanisms in tendon and uncovers key insights into tendon homeostasis in
unique loading environments. Our approach addressed the following aims:
Aim 1: Delineate the role of biglycan and collagen VI in regulating tendon
properties. We employed mouse models deficient in biglycan, collagen VI, or both
molecules to define the differential roles of each molecule in regulating tendon
properties. We compared tendon fibril morphology and biomechanical properties across
each knockout mouse model to contrast the regulatory roles of biglycan and collagen VI.
This approach tested the hypothesis that: (1) both molecules are critical regulators of
tendon properties, (2) collagen VI regulation in tendon is more robust than that of
biglycan, and (3) the roles of biglycan and collagen VI in tendon are additive.
Aim 2: Elucidate the mechanisms by which biglycan balances tenogenicity
across distinct tendon loading environments. We crossed a Scx-targeted Bgn
conditional knockout mouse model with a Scx-GFP reporter line to define how biglycan
15

regulates tendon cell fate within unique tendon regions. We compared tendon gene
expression and tensile mechanical properties in the presence and absence of biglycan
to evaluate the tenogenic tissue state. This approach tested the hypotheses that: (1)
biglycan knockout decreases the presence and tenogenic gene expression of Scx-GFP+
cells while increasing the cells’ chondrogenic gene expression, (2) these cellular
changes correspond with decreased tensile properties, and (3) tenogenic decreases with
biglycan knockout are more robust in the tendon midsubstance than in the wrap-around
region due to pre-existing tenogenic deficits in the wrap-around region.
Aim 3: Define the role of biglycan in regulating tendon PCM properties across
distinct tendon loading environments. We crossed A Scx-targeted Bgn conditional
knockout mouse model with a Col6a1-GFP reporter line to determine how biglycan
regulates the presence and behavior of PCM-synthesizing cells within unique tendon
regions. PCM gene expression and matrix analysis defined how biglycan regulates the
tendon PCM. This approach tested the hypotheses that: (1) biglycan knockout disrupts
normal PCM structure, (2) this abnormal structure will perturb native tendon cells and
cause a compensatory increase in PCM synthesis, and (3) these changes are more
robust in the wrap-around region due to increased reliance on the PCM in the wraparound region.
1.8. Chapter Overview
Chapter II describes the differential roles of biglycan and collagen VI in regulating
tendon properties. Chapter III describes the regional development of the FDL tendon,
the PCM presence through this regional development, and the impact of biglycan
knockout on the properties of these distinct regions. Chapter IV provides conclusions
from this work and future directions of study.
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CHAPTER 2: COORDINATE ROLES FOR BIGLYCAN AND COLLAGEN VI IN
REGULATING TENDON COLLAGEN FIBRIL STRUCTURE AND FUNCTION
This chapter is based on work published in Leiphart, RJ et al. Coordinate roles for
collagen VI and biglycan in regulating tendon collagen fibril structure and function. Matrix
Biol. Plus 13, (2021).1
2.1. Introduction
Tendon is a unique tissue that connects muscle to bone and is therefore critical
in transmitting forces for skeletal movement and stability. Tendon pathology, with origins
ranging from genetic mutations to physical overuse and injury, presents a significant
clinical problem for a wide range of patients.2–4 Due to the poor self-healing capacity of
tendons, tissue engineering and other therapeutic approaches to tendon repair have
been largely unsuccessful. Better understanding of the functional interplay between the
tendon matrix and cell biology is needed to augment current tendon pathology treatment
paradigms.
While the tendon extracellular matrix (ECM) is dominated by collagen I fibrils, the
matrix is composed of a diverse set of other collagens and proteins. Collagen I fibrils
play a dominant role in dictating tendon mechanical strength; however, these fibrils are
tightly regulated by other collagens and non-collagenous proteins present in tendon.5–7
Previous studies have shown that matrix molecules interact to properly organize
collagen I fibrils and maintain tendon mechanical integrity.8–11 The fundamental
mechanisms by which these ECM components cooperatively maintain tendon function,
however, remain elusive.
Small leucine-rich proteoglycans (SLRPs), such as biglycan, are critical matrix
regulators in many skeletal and non-skeletal tissues.12,13 SLRPs consist of a small core
protein containing leucine rich repeats (LRR) and attached glycosaminoglycan (GAG)
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chains. Previous studies demonstrate that the LRR motifs in the SLRP core protein
permit binding to fibrillar and non-fibrillar collagens, thereby regulating collagen fibril
growth and assembly.14 In tendon, these SLRPs, especially biglycan, are key regulators
of mechanical and structural properties. Biglycan deficiency results in irregular collagen
fibril architecture.9,15 Such changes correspond with decreased tendon mechanical
properties and joint function.16–20 Previous work also implicates biglycan in regulating
tendon stem cell fate.21 While biglycan has been shown to be a key regulator of tendon
physiology, the ECM interactions behind this functional regulation are unknown.
Collagen VI is another abundant matrix component in tendons. This non-fibrillar
collagen molecule is composed of three interwoven α-chains with a central triple helical
domain and terminal non-collagenous domains. These molecules assemble into
tetramers before forming an extracellular “beaded microfilament” network.22 Prior
research shows that collagen VI interacts with numerous ECM components, including
collagen I, collagen II, decorin, and biglycan.23–25 Collagen VI often localizes to
pericellular regions of musculoskeletal tissues, suggesting it has roles related to cellmatrix interactions.26–29 In this context, it is theorized that collagen VI may serve as a
“bridge” between cells and the ECM, thereby playing important roles in cell
mechanosensation and cell surface growth factor modulation. Mutations in genes
encoding collagen VI cause Bethlem myopathy or Ullrich congenital muscular dystrophy
(UCMD), which manifest with muscular weakness and connective tissue abnormalities.30
In cartilage, collagen VI is the main component of the pericellular matrix (PCM), which is
a key structure for mechanotransduction and for maintaining proper cell function.27
Collagen VI has been shown to influence proper collagen fibril assembly and regulate
tendon function.26 However, the specific role(s) of collagen VI in tendon remain
understudied.
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In addition to their individual roles in regulating tendon function, evidence
suggests that biglycan and collagen VI may interact with each other within the matrix.
When combined in vitro, biglycan binds to collagen VI and organizes the fibrils into a
hexagonal, mesh-like network.31 This filamentous network resembles a PCM previously
observed in tendon.32 This dual-molecule structure suggests that biglycan and collagen
VI function cooperatively within tendon. Therefore, the objective of this study was to
define the impact of biglycan and collagen VI on tendon structural and functional
properties using single or combined knockout models. We hypothesized that the two
molecules have epistatic roles, and that a dual knockout would lead to further decreases
in tendon properties than depletion of either molecule alone.
For this work, the dissertation author helped conceptualize the study, collected
and analyzed mechanical data, interpreted study results, and drafted the manuscript.
2.2. Methods
Animal Use
All animal treatment and care conformed to NIH guidelines and were approved
by Carnegie Institution Animal Care and Use Committee (ACUC) for the tendon repair
model and the NIH-DIR ACUC (#18-865) for TEM and biomechanical studies. C57BL6/J
strain (WT) was purchased from Jackson Laboratory. Male WT mice were used for deep
RNA-seq and injuries for immunohistochemical presentation. Wild-type, Col6a2-/-, Bgn-/0
and Col6a2-/-;Bgn-/0 mice derived either in house (Bgn-/0)33 or in the lab of Carsten
Bonnemann (NINDS, NIH-DIR, Col6a2-/-).
Deep RNA-seq
For injured/regenerated samples, whole patellar tendon pairs were isolated in
triplicate. Samples were collected during the same time window to mitigate any batch
effects. Isolated tendons pairs were minced with dissecting scissors, transferred to 15mL
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conical tubes containing prewarmed 10mL of 1X PBS (Gibco), 4mg/mL dispase II
(Sigma), and 3mg/mL collagenase (Worthington). Conical tubes were transferred and
positioned horizontally in a shaking 37oC water bath for 1.5hr. Following this, enzymes
were deactivated with 3mL TSPC specialized media, run through a 40μm filter, and
pelleted at 300xg for 30’ @ 4oC. The cell pellet was washed with 1mL 1X PBS (Gibco)
and re-pelleted at 300xg for 15’ @ 4oC. The cell pellet was subsequently lysed for RNA
preparation using the RNA Direct-zol kit (Zymo), followed by Ovation RNA-seq V2
System (NuGEN) to generate cDNAs. cDNAs were then sonicated to 300-500bp range
(Covaris) and libraries were generated by the TruSeq RNA Library Prep Kit (Illumina) for
single-end 75bp reads (Next-seq, Illumina). Reads were mapped and aligned to the
mm10 reference genome using TopHat.34 Read count normalization was determined by
HTSeq35 and differential expression analysis across the temporal samples was
assessed by the R package, DESeq.36 Normalized, relative count data are represented
as FPKM values in visualizations using GraphPad.
Patellar Biopsy Punch Surgical Procedure
Bilateral biopsy punch was performed as described previously37 with the
following modifications: A #5 forcep (Dupont) was used to expose the underside of the
patellar tendon. A small, thin metal sheet was placed underneath the tendon to provide a
backing for the excisional biopsy punch. An Accu-Sharp Punch MII 0.75 mm diameter
(Shoney Scientific) was used. Skin lesion was closed using sutures (Ethicon, PERMAHANDTMSilk, 5- 0, P-3). Mice were placed in a heated chamber to recover from
anesthesia. Elizabethan collars were put on the mice for the first 3 days following
operation. Knee joints were harvested for assay at specified time points for assays.
Knee joints were harvested for analysis at specified time points for the assays
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performed. For immunohistochemistry, samples were collected 3 days post-surgery prior
to processing.
Tissue preparation and cryo-sectioning
Knee joints were dissected out in PBS (Gibco) as described 38 with modifications
described37: 20μm sagittal sections were collected on Cryofilm Type IIC (Section Lab,
Inc., Japan) and affixed to glass slides using 1.5% chitosan in 0.25% acetic acid and
allowed to dry at 4oC before use. Sections throughout the tendon were collected.
Immunohistochemistry
Dried sections were hydrated with PBS, permeabilized 15’ with PBS plus 0.5%
Triton X-100 (w/v; 0.5% PBT), rinsed with 0.05% PBT, and then treated with ABCase
(per manufacturer guidelines) for 1h @ 37oC. Following this, they were rinsed with PBT
2X for 5’, endogenous peroxidase activity was quenched with 3% H2O2 in PBS for 10’,
and next rinsed with PBT 2X for 5’. Slides were subsequently treated for 1h @ 37oC with
10% normal goat serum in PBS. Serial sections were incubated with primary antibodies
diluted in ABC blocking solution (Vector Labs) overnight at 4oC. Primary antibodies used
were rabbit anti-Collagen VI: 1:200 dilution (70R-CR009x, Fitzgerald, USA) rabbit antiBgn (in house made: LF-159): 1:500 dilution. Negative controls were 1:200 dilution of
rabbit IgG 1:500 dilution of normal rabbit serum respectively.
Following primary incubation, slides were washed with 0.05% PBT 3-5X for 5’ each,
Avidin/Biotin Block (Vector Labs, according to manufacturer), followed by a quick rinse
with PBT. Sections were then incubated for 30’ with diluted biotinylated, goat anti-rabbit
secondary antibody (Vectastain by Vector), washed 3X with PBT, and subsequently
incubated for 30’ with Vectastain ABC reagent (Vector). Following formation of the super
complex, slides were washed 3X with PBT, then incubated with DAB substrate (Vector)
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for immunohistochemistry until color developed. Lastly, slides were washed with PBT 5X
for 5’ each to quench reaction. Sections were counterstained with Gill’s Hematoxylin
(Vector) for 15’ according to manufacturer. Sections were dehydrated through a graded
ethanol series (50, 75, 95, 100, 100 %, then Xylene; 30” each) and mounted with
Permamount (EMS).
Images were taken on a Nikon Eclipse E800 scope equipped with Plan Fluor Apo
objectives (magnification/numerical aperture; 4x/0.13, 10x/0.45, 20x/0.75) and captured
with a Canon EOS Rebel T3i camera and EOS Utility software.
Transmission electron microscopy
Flexor digitorum longus (FDL) tendons from 60 day-old mice (n=4
tendons/genotype from minimum of n=3 mice/genotype) were prepared for analysis of
fibril structure by transmission electron microscopy as previously described.39,40 Tendon
samples were collected in the morning hours (8AM-12PM local time) to mitigate any
effects of circadian regulation on collagen fibril size.41 Briefly, tendons were fixed in 4%
paraformaldehyde, 2.5% glutaraldehyde, 0.1 M sodium cacodylate and 8 mM CaCl2,
adjusted to pH 7.4 with NaOH, then post-fixed with 1% osmium tetroxide, dehydrated
with an ethanol series, embedded in Epon 812 and polymerized at 60°C. Ultra-thin
cross-sections of were imaged on a JEOL 1400 transmission electron microscope (JEOL
Ltd., Tokyo, Japan) equipped with a Gatan Orius widefield side mount CC Digital camera
(Gatan Inc., Pleasanton, CA). Digital images (n=32/tendon) from the mid-substance of
each tendon were taken from non-overlapping areas at 60,000X. Images were
randomized and masked before fibril diameters were measured using an RM BiometricsBioquant Image Analysis System (Nashville, TN). A region of interest (ROI) of
appropriate size was determined within each digital image. All fibrils in the region of
interest were measured and 33-63 regions of interest were used to collect at least 80
35

fibril diameter measurements per image. Fibril diameters (2691-3288 depending on
genotype) were measured along the minor axis of the fibril cross-section. Fibril diameter
measurements from tendon of each genotype were pooled and graphed by histogram in
5 nm bins (x-axis) vs frequency (%, y-axis) and displayed by box-plot. A two-sample
Kolmogorov–Smirnov (K-S) test (p<0.05) was used to assess sameness of the
distributions between genotypes. Mean fibril density was presented by tendon in a dotchart and paired Student’s t-test (p<0.05) was used to assess for significance between
genotypes.
Biomechanical Testing
To assess FDL tendon mechanical properties, two month-old male wild-type
(WT) (n=16), Col6a2-/- (n=11), Bgn-/0 (n=12), and Col6a2-/-;Bgn-/0 (n=13) mice were used.
FDL tendons were dissected from the left hind limb and the tendon sheath fine dissected
off the tendon. Tendon cross-sectional area (CSA) was measured with a custom laser
device, and stain lines were applied for optical tracking.42 The FDL tendon was gripped
with sandpaper, leaving a 5mm gauge length. This gauge length spans the main body of
the tendon, starting at the convergence of the tendon digits and ending near the
myotendinous junction.
For biomechanical testing, samples were loaded in a phosphate buffered saline
bath within a uniaxial tensile testing machine (Instron 5542, Instron, Norwood, MA). The
testing protocol consisted of 10 cycles of preconditioning between 0.01-0.02N at 1Hz, a
5-minute hold, a 5% stress relaxation for 10 minutes, a 1-minute hold, and a ramp to
failure at 0.5% strain/s. Stress relaxation, stiffness, and maximum load were computed
from force-displacement data. Modulus and maximum stress were computed using
optical tracking and normalization to CSA. Dynamic collagen fiber realignment was
measured throughout the ramp-to-failure test using a crossed polarizer setup.43
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For mechanical properties, a one-way ANOVA with Bonferroni post-hoc tests
was used to compare across genotypes. For fiber realignment data, a two-way ANOVA
with Tukey correction for multiple comparisons was used to compare across genotype
and strain. Significance was set at p<0.05, and trends were set at p<0.1.

2.3. Results
2.3.1. Expression of Collagen VI and Biglycan in Healing Tendons
To clarify how collagen VI and biglycan might cooperate within tendon, we assessed
their co-expression and co-localization within healing tendons, as tendon healing
recapitulates aspects of tendon matrix formation (Figure 2-1).44–46 Upregulation in gene
expression and protein presence during healing therefore suggests similar patterns and
potential function through other tendon matrix contexts, including formation or growth.
We used a mouse tendon injury punch model47 and performed bulk RNA-Seq in weekly
intervals throughout the subsequent healing process. Temporal RNA-Seq revealed that
increases in Bgn transcripts corresponded with increases in transcripts encoding the
three primary collagen VI genes [Col6a(1-3)]. RNA expression of these genes rose
above uninjured control levels by 1-week post-injury, peaked at 2-weeks post-injury, and
returned to uninjured levels by 4-weeks post-injury. Unsupervised clustering of Bgn and
Col6 RNA-Seq data grouped 1- and 2-weeks post-injury samples together, further
supporting upregulation of these genes during these healing timepoints (Figure 2-2).
These expression dynamics are consistent with many injury-responsive tendon genes.37
De novo tendon matrix formation occurs within the first two weeks following injury.
Elevated Bgn and Col6a1, Col6a2, and Col6a3 expression during this healing window
suggests that biglycan and the dominant a1(VI)a2(VI)a3(VI) form of collagen VI play key
roles in tendon matrix formation during repair. We next sought to visualize where
37

collagen VI and biglycan proteins localize within healing tendons. Immunohistochemistry
on serial sections of the healing patellar tendon showed enrichment for both molecules
in and around the injury site, further implying critical roles of these molecules in
regulating nascent tendon matrix production (Figure 2-1B).

Figure 2-1. Collagen VI and biglycan are co-expressed and co-localize within healing
tendon. A. Relative fragments per kilobase million (FPKM) RNA counts for Bgn (left axis)
and Col6 (right axis) genes revealed consistent injury-responsive expression patterns in
these genes. Following injury, expression of these genes rose above uninjured levels by 1week post-injury, peaks at 2-weeks post-injury, and returned to near-baseline levels by 4weeks post-injury. Results are from isolated tendon pairs (n=3 tendons). B.
Immunohistochemistry staining of ColVI and Bgn on post-injury tendon sections at low
magnification (left image) and high magnification of red inset (right image) showed colocalization of these molecules during tendon healing. Healing biopsy punch site is boxed in
red in lower magnification image. Size bars = 100μm.

2.3.2. Collagen Fibril Structure
We elucidated the structural impact due to loss of biglycan, collagen VI, or both
molecules on collagen fibril architecture in mature tendons. The models used were
global knockouts of biglycan (Bgn-/0 ) and/or collagen VI (Col6a2-/-), the latter of which
results in a total loss of collagen VI trimer secretion.33,48 TEM images of FDL tendon
sections were analyzed from 2 month-old WT, Bgn-/0, Col6a2-/-, and Col6a2-/-;Bgn-/0 mice
(Figure 2-3). Our results showed that qualitatively, fibril shape was comparable across
groups with roughly circular fibril cross-sections in all 4 genotypes. Fibril diameter
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distribution in Bgn-/0 tendons was similar to that of WT tendons, with a moderate shift
towards smaller diameter fibrils (median WT value 138.5nm vs 111.2nm in Bgn-/0 mice).
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Figure 2-3. Biglycan and/or collagen VI deficiency disrupted tendon collagen fibril
size. (A) WT FDL tendons displayed a bimodal distribution of large (~160nm diameter)
and small (<100nm diameter) collagen fibrils. (B) Bgn-/0 FDL tendons demonstrated a
moderate shift towards smaller fibril diameters while maintaining a bimodal distribution.
(C) Col6a2-/- FDL tendons contained a significantly larger proportion of small diameter
fibrils with decreased presence of large fibrils. (D) While Col6a2-/-;Bgn-/0 FDL tendons
also displayed a prominent shift towards small diameter fibrils, they contained an
increased proportion of larger fibrils compared to Col6a2-/- FDL tendons. Fibril
measurements were collected across n=4 tendons/genotype from n>3 mice/genotype.

40

knockout tendons is interesting, as this would not be predicted by combining the effects
of each single knockout model. This result suggests that biglycan and collagen VI play
synergistic, rather than additive, roles in regulating tendon fibril structure. Fibril density
(fibril number/μm2) was significantly increased in single and double KO genotypes
compared to WT tendons (Figure 2-4). However, Col6a2-/- tendons had greater fibril
density than that of Bgn-/0 tendons. This was expected given the larger proportion of
smaller fibrils in knockout tendons, especially in the single collagen VI knockout group.

Figure 2-4. Collagen fibril size distributions and fibril density were altered with
biglycan and/or collagen VI deficiency. (A) Box and whisker plots of collagen fibril size
distributions demonstrated a decrease in the median size of collagen fibrils in FDL
knockout tendons. Kolmorogov-Smirnov tests demonstrated that each distribution was
distinct from those of all other genotypes (p<0.001). (B) Given the increased proportion
of small diameter fibrils in collagen VI-null tendons, Col6a2-/- and Col6a2-/-;Bgn-/0 FDL
tendons had increased fibril density compared to WT and Bgn-/0 tendons. Bars indicate
p<0.05 for paired Student’s t-tests. Fibril measurements were collected across n=4
tendons/genotype from n>3 mice/genotype.
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In addition to the fibril changes that resulted from collagen VI and/or biglycan
deficiency, we defined the impact of loss of these molecules on tendon cell (tenocyte)
morphology within the higher order tissue structure. In lower magnification TEM images
of healthy WT tendons, tenocytes are organized in uniaxial columns with cellular
processes extending perpendicular to the tendon axis and partitioning collagen fibrils
within larger fibers (Figure 2-5). In Bgn-/0 tendons, this morphology was preserved, as
tenocytes exhibited long cytoplasmic processes radiating from the tenocyte body and
separating groups of fibrils. However, this normal morphology was disrupted in both
collagen VI knockout genotypes. Collagen VI-null tenocytes had shortened and
disorganized cytoplasmic processes that incompletely partitioned adjacent fibrils. The
surface of these tenocytes was also separated from the pericellular fibrillar matrix, which
was not apparent in WT or Bgn-/0 tendons. Associated with the poorly developed
tenocyte processes, collagen VI-null tendons demonstrated less organized grouping of
fibrils into fibers compared to WT and Bgn-/0 tendons.
2.3.3. Biomechanical Characteristics
Given the structural changes to the collagen fibril network seen in collagen VI
and biglycan-null tendons, we next tested whether their mechanical properties were
affected (Figure 2-6). Cross-sectional area (CSA) was reduced with loss of biglycan,
collagen VI, or both molecules. Col6a2-/- and Col6a2-/-;Bgn-/0 tendons also had smaller
CSA than Bgn-/0 tendons. Deficiency in biglycan, collagen VI, or both molecules resulted
in weaker tendons without decreasing tendon material properties. Tendons from all
knockout genotypes were less stiff and had lower maximum loads than WT tendons.
Col6a2-/- and Col6a2-/-;Bgn-/0 tendons were less stiff than Bgn-/0 tendons, and
Col6a2-/-;Bgn-/0 tendons had lower maximum loads than Col6a2-/- and Bgn-/0 tendons. No
differences in moduli were observed between any of the groups (Figure 2-7). Col6a2-/42

Figure 2-5. Tenocyte processes and morphology were perturbed with biglycan and/or
collagen VI knockout. Tenocytes are organized into uniaxial columns with processes
extending perpendicular to the tendon axis. This higher order tendon structure is
comparable in WT and Bgn-/0 tendons with long cytoplasmic processes (red arrows)
radiating out from the tenocyte and partitioning the fibrillar matrix. (Fig. 4 A,B). In contrast,
both Col6a2-/- and Col6a2-/-;Bgn-/0 tenocytes had shortened, disorganized cytoplasmic
processes that incompletely partitioned the adjacent fibers (Fig. 4 C,D). In the collagen VI
deficient genotypes, there was a separation of the tenocyte surface from the tendon fibrillar
matrix (White arrow heads). This apparent lack of pericellular adhesion was not observed in
the WT or Bgn-/0 tendons. In addition, both fibrils and fibers were less organized compared
to WT and Bgn-/0 tendons.

and Col6a2-/-;Bgn-/0 tendons had higher maximum stresses than WT and Bgn-/0 tendons.
Loss of collagen VI reduced tendon viscoelasticity, as Col6a2-/- and Col6a2-/-;Bgn-/0
tendons exhibited lower percent relaxation than WT and Bgn-/0 tendons.
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Figure 2-6. Biglycan and/or collagen VI deficiency caused reductions in tendon crosssectional area and structural-mechanical properties. (A) WT tendons had a larger CSA
than all knockout genotypes. Bgn-/0 tendons had larger CSA than collagen VI knockout
tendons. (B) WT tendons were stiffer than all knockout genotypes. Bgn-/0 tendons were
stiffer than collagen VI knockout tendons. (C) WT tendons had a higher maximum load than
all knockout genotypes. Bgn-/0 and Col6a2-/- tendons had higher maximum loads than
Col6a2-/-;Bgn-/0 tendons. Bars indicate p<0.05 from one-way ANOVAs with Bonferroni posthoc comparisons.

We quantified the collagen fiber realignment dynamics of tested tendons during
ramp to failure to elucidate genotype-dependent load-bearing mechanisms (Figure 2-8).
Biglycan loss led to delayed fiber realignment compared to WT. During the ramp to
failure, WT tendons realigned between 3% and 5% strain while Bgn-/0 tendons realigned
between 5% and 7% strain. Col6a2-/- and Col6a2-/-;Bgn-/0 tendons realigned earlier in
response to load, between 1% and 3% strain. At 3% and 5% strain, Bgn-/0 tendons were
less aligned than Col6a2-/- and Col6a2-/-;Bgn-/0 tendons and trended towards less
alignment than WT tendons (Figure 2-9).

Figure 2-7. Collagen VI knockout resulted in changes to tendon viscoelastic and
material properties. (A) No differences in moduli were observed between genotypes. (B)
Both collagen VI knockout tendons had higher maximum stresses than WT and Bgn-/0
tendons. (C) WT and Bgn-/0 tendons exhibited more stress relaxation than collagen VI
knockout tendons. Bars indicate p<0.05 from one-way ANOVAs with Bonferroni post-hoc
comparisons.
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This mechanical data demonstrates that both biglycan and collagen VI play
critical roles in regulating FDL tendon mechanical properties. Knockout of either
molecule, or both in unison, led to reductions in tendon CSA, stiffness, and maximum
load. Collagen VI knockout led to larger reductions in mechanical properties than seen in
biglycan deficient tissues, suggesting that collagen VI plays a larger role in regulating
tendon mechanics. The regulatory roles of collagen VI and biglycan are also distinct.
Collagen VI knockout reduced tendon viscoelasticity, while biglycan deficiency did not

Figure 2-8. Fiber realignment dynamics during ramp to failure were altered across
knockout models. (A) WT tendons realigned between 3% and 5% strain. (B) Col6a2-/tendons realigned earlier than WT tendons, between 1% and 3% strain. (C) Bgn-/0
tendons realigned later than WT tendons, between 5% and 7% strain. (D) Col6a2-/-;Bgn/0 tendons realigned earlier than WT tendons, between 1% and 3% strain. Solid bars
indicate p<0.05, and dashed bars indicate p<0.1 from one-way repeated measures
ANOVAs with Tukey post-hoc comparisons.
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appreciably impact viscoelasticity. Biglycan loss led to delayed fiber realignment
compared to WT tendons, while collagen VI-deficient tendons realigned earlier in the
ramp to failure than WT tendons. Despite these distinct roles, the effects of biglycan and
collagen VI deficiency on tendon mechanics were not additive. Tendons deficient in both
molecules mechanically behaved like tendons deficient in collagen VI alone. While
knockout tendons displayed decreased structural-mechanical properties (stiffness and
maximum load), these changes did not correspond with changes in modulus. Maximum
stress was surprisingly increased in collagen VI knockout tendons, the opposite effect
seen with maximum load. These results are in part due to initial differences in tendon

Figure 2-9. Biglycan-null tendons were less aligned at middle strains during ramp to
failure. At 3% and 5% strain Bgn-/0 tendons were less aligned than Col6a2-/- and Col6a2-/;Bgn-/0 tendons and trended towards less alignment compared to WT tendons. Solid bars
indicate p<0.05, and dashed bars indicate p<0.1 from two-way ANOVAs with Tukey posthoc comparisons.
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geometry. Tendons from all mutant genotypes had reduced size compared to WT
tendons, and collagen VI knockout tendons were smaller than both WT and Bgn-/0
tendons. In conclusion, both collagen VI and biglycan regulate FDL tendon mechanics,
with collagen VI being a more robust effector.
2.4. Discussion
Overall, our data indicates that collagen VI and biglycan play critical roles in
regulating tendon function that are unique and non-additive. Injured tendons co-express
and co-localize these matrix proteins within the healing tissue. Since tendon healing
recapitulates aspects of tendon matrix formation, these results suggest that collagen VI
and biglycan may also cooperate during matrix formation of developing tendons. While
this experiment analyzed healing tendons rather than developing tendons, our results
are corroborated by prior studies demonstrating increased expression of collagen VI and
biglycan during early tendon formation.49,50 Co-expression and co-localization of collagen
VI and biglycan during tendon healing also supports prior in vitro evidence that the two
molecules are capable of binding and interacting in a manner that changes their
architecture.25,31
Despite their co-residence within tendon tissue, loss of collagen VI or biglycan
led to different structural and mechanical changes to the tendon. Collagen VI knockout
resulted in a larger proportion of small diameter collagen fibrils than seen with biglycan
knockout alone. Tenocyte morphology was also perturbed with collagen VI deficiency
but was relatively preserved with biglycan knockout alone. These robust matrix changes
in collagen VI-null tendons corresponded with larger deficits in mechanical properties
compared to Bgn-/0 tendons. The more robust functional deficits seen in collagen VI-null
tendons compared to biglycan-null tendons indicates that the molecules may play
different roles in regulating tendon properties, and that collagen VI plays a more
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substantial regulatory role than that of biglycan. Interestingly, when collagen VI and
biglycan were knocked out together, resultant tendon properties closely mimicked those
of the collagen VI knockout alone. Aside from increased proportion of larger diameter
collagen fibrils and decreased maximum load, no measured properties were statistically
different between Col6a2-/- and Col6a2-/-;Bgn-/0 tendons. This demonstrates that the roles
of collagen VI and biglycan are not additive, as further loss of biglycan in collagen VI-null
tendons did not lead to substantial changes compared to collagen VI single knockout
tendons.
Results of the current study may be explained by proposed models of the tendon
pericellular matrix (PCM). When combined in vitro, biglycan organizes collagen VI fibrils
into a hexagonal mesh-like network, with biglycan occupying vertices within this mesh.31
This mesh-like network resembles the in situ structure of the tendon PCM, of which
collagen VI is a large component.32 This study demonstrated co-expression and colocalization of these molecules in healing tendon, providing further evidence of their
interaction. Assuming this model of the tendon PCM, the PCM may be analogous to a
“house of cards” that is taped together. In this analogy, biglycan serves as the stabilizing
“tape” and without “tape”, the structure is unstable and more easily perturbed. While this
has a deleterious effect on tendon function, absence of the “house of cards” altogether
would have a larger effect than absence of the binding “tape” alone. This may be why
the collagen VI knockout led to more severe functional deficits – the PCM was disrupted
beyond the “de-stabilization” seen with biglycan knockout. This model would also explain
the similar tendon outcomes observed between the collagen VI single knockout and the
collagen VI/biglycan double knockout. Since the main structure of the PCM is already
absent in the collagen VI knockout, the additional knockout of biglycan does not result in
further robust changes, as biglycan’s role in organizing the PCM is less relevant. This
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paradigm of co-dependent function likely holds true during tendon regeneration, where
we found co-expression and co-induction of collagen VI and biglcyan through the tendon
healing process.
While the focus of this report was on the role of collagen VI α2 and biglycan on
the structure and function of tendons, it is important to consider what role different
chains of collagen VI (i.e., Col6a5 and Col6a6) or other SLRPs have in tendon biology.
In addition to this, the possible interface with other molecular influences such as TGF-β
must also be considered. Sabetelli et al, showed that TGF-β1 differentially regulates
collagen VI α5 and α6 chains in human tendon cultures.51 Biglycan is also affected by
TGF-β activity in healing tendons.52 In this context, it is interesting to speculate that a
TGF-β signaling loop controls many aspects of tendon healing related to matrix biology,
including the production of collagen VI chains, biglycan, and potentially other SLRPs.
Future studies are needed to determine if or how different collagen VI chains are
affected during tendon healing and how this in turn could affect tendon structure and
function.
An important cellular aspect not addressed in the manuscript is the possible role
of biglycan and collagen VI in modulating macrophage function during tendon healing.
Previous work shows biglycan can control macrophage function via CD14 activation.53 In
kidney disease, biglycan appears to regulate macrophage autophagy through molecular
interactions involving the CD44/Toll-like Receptor4 axis.54 Interestingly, other work
shows there is an increased number of M1 macrophages in the first two weeks after
tendon injury and a subsequent increase of M2 macrophages during regeneration,55
suggesting that subsets of macrophages may have different functions during tendon
healing. Considering collagen VI is abundantly produced by M2 polarized
macrophages,56 it is tempting to speculate that collagen VI plays roles in tendon repair
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related to M2 function. It will be interesting to determine the expression pattern of
biglycan and collagen VI during macrophage infiltration in the tendon injury model and,
further, to see if the absence of the biglycan, collagen VI, or both could influence
macrophage function during tendon healing.
In conclusion, our data clearly demonstrates non-additive roles for biglycan and
collagen VI in regulating tendon properties, supporting models of coordinate function
between these molecules within the tendon matrix. Understanding more about their
functions in tendon homeostasis could provide a foundation for therapeutics that aim to
restore tendon function following injury or degeneration.
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CHAPTER 3: THE PERICELLULAR MATRIX IS INVOLVED IN THE BIGLYCANREGULATED DEVELOPMENT OF REGIONAL FDL TENDON PROPERTIES
3.1. Introduction
Tendon is a key musculoskeletal tissue that aids in locomotion by transmitting
muscle contraction forces to bone. To properly function as a tensional transducer,
tendon tissue is dominated by hierarchically structured collagen I fibers.1 This organized
tissue matrix provides a “tenogenic” environment - an environment of highly aligned
collagen in which resident tendon cells (tenocytes) preserve their native phenotype,
properly sense tissue forces, and maintain tendon homeostasis. In tendon disease
(tendinopathy), the aligned matrix degenerates and becomes disorganized.2,3 This loss
of matrix “tenogenicity” corresponds with tenocytes assuming a chondrogenic phenotype
and an increased proportion of cartilaginous matrix molecules. Degenerative changes to
the tendon matrix disrupt its mechanical properties, resulting in further degeneration and
increased injury risk.4 Despite the debilitative outcomes of tendinopathy, there is a
dearth of knowledge surrounding the causes, progression, and prevention of this
degeneration. To properly treat tendon disease, the governing mechanisms by which
tendon loses its matrix and cell phenotype must be elucidated.
Although the tendon extracellular matrix (ECM) is dominated by collagen I fibers,
other matrix proteins play key roles in maintaining tissue tenogenicity. One such matrix
molecule is biglycan, a small, leucine-rich proteoglycan (SLRP).5 Biglycan is implicated
in regulating tenogenic properties due to heightened expression during tendon
development6,7 and a suggested role within the tendon stem cell niche.8 Biglycan
knockout results in tendons with abnormal collagen fibril size and decreased mechanical
properties.9–11 These studies demonstrate that biglycan deficiency reduces tenogenic
properties, resulting in decreased tissue function. Tendinopathic tendons also display
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increased biglycan expression and protein levels, further supporting a critical role of
biglycan in modulating tenogenicity.12,13 Despite biglycan’s important role in tendon, the
mechanisms by which biglycan controls native tendon phenotype remain unknown. By
elucidating these regulatory mechanisms, the factors and stimuli most vital for tendon
health may be revealed.
While tenogenic matrix loss is a hallmark of tendinopathy and of biglycan
deficiency, there are healthy contexts in which tendon also possesses reduced
tenogenicity. Tendons that “wrap-around” joint spaces, such as flexor tendons spanning
the wrist or ankle joints, contain a unique matrix with fibrocartilage features. In these
“wrap-around” regions, collagen fibers are less aligned, and resident tenocytes maintain
a rounded morphology that is indicative of a (fibro)chondrogenic phenotype.14,15 The
local matrix contains increased glycosaminoglycan (GAG) content, further differentiating
this fibrocartilaginous matrix from one of normal, healthy tendon. Prior studies have
shown that this unique tissue phenotype is caused by complex forces, including
compression, imparted on the wrap-around tendon during joint flexion. Ex vivo
compression elicits increased GAG production in tendon explants.16–18 The wrap-around
tendon region has a stronger response to applied compression than that of the normal,
“tensile” tendon region. Further, when wrap-around tendons are translocated and are no
longer exposed to complex joint forces, the fibrocartilaginous matrix phenotype
recedes19. Together, these studies demonstrate that resident tenocytes lose tenogenicity
in response to complex and compressive forces, that these forces “prime” tenocytes for
further reductions in tenogenic phenotype, and that this response is plastic and
reversible. Wrap-around tendons have provided key insight into tenocyte
mechanosensitivity.
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Given the implication of non-physiological forces initiating or exacerbating tendon
degeneration,20 there is a need to understand mechanosensitive mechanisms for tendon
regulation. Wrap-around tendons can be used to study these mechanisms, as they
represent healthy contexts of tenogenic drift and do not involve confounding, underlying
pathologies seen in tendinopathy. Therefore, wrap-around tendons may serve as a
model system for research into how specific matrix molecules and structures regulate
tenocyte behavior and resulting tendon function across distinct loading environments.
Such understanding would inform tendinopathy treatment paradigms. Interestingly,
biglycan is up-regulated in the fibrocartilage regions of wrap-around tendons,21,22
providing motivation to study biglycan regulation of tenogenic properties using wraparound tendons as a model system.
In considering the mechanosensitive mechanisms of musculoskeletal tissues, the
pericellular matrix (PCM) is likely a critical regulator. The PCM is a specialized matrix
that immediately surrounds cells, especially in cartilage and fibrocartilage.23 With its
cellular proximity, the PCM directly transduces matrix forces to the cell and serves as a
signaling ligand reservoir.24,25 Given these properties, the PCM is a large driver of cell
fate and behavior. The PCM is implicated in degenerative diseases such as
osteoarthritis,26,27 further demonstrating the importance of this matrix structure for tissue
homeostasis. The tendon PCM has been shown to envelop linear arrays of tenocytes.28
Despite its well-researched role in cartilage and fibrocartilage, little is known about the
PCM in tendon and its role in regulating tissue properties. Investigating the role of the
tendon PCM in dictating tenocyte behavior will likely uncover critical stimuli and factors
that augment or reduce tissue tenogenicity.
The PCM is comprised of several matrix molecules that are robust tendon
regulators, including collagen VI and biglycan. Collagen VI is a non-fibrillar collagen that
59

aggregates into tetramers and forms a hexagonal mesh in the extracellular space.29
Collagen VI is the primary component of the PCM and thus plays a large role in tissue
homeostasis, including in tendon. Tendons deficient in collagen VI display decreased
mechanical properties, in part due to altered collagen fibril architecture within the tendon
body.30 Like collagen VI, biglycan may regulate tendon properties through the PCM.
Biglycan localizes pericellularly31 and organizes collagen VI fibrils into a hexagonal
network reminiscent of typical PCM structure.32 Thus, biglycan may serve as a structural
“glue” that maintains PCM integrity. Although evidence alludes to a PCM-centric
mechanism whereby collagen VI and biglycan cooperate to maintain tissue function,33
knowledge of this mechanism remains elusive.
The objective of this work was to define the development of regional properties in
the FDL tendon, with a focus on PCM presence between unique tendon regions, and to
delineate the response of each region to biglycan knockout. To address this objective,
we performed gene expression, histological, and mechanical analyses on murine FDL
tendons from various knockout and cell reporter mouse lines. We hypothesized that the
wrap-around region of the FDL tendon contains higher presence of PCM molecules
compared to the tensile region and that the wrap-around region will be more sensitive to
biglycan deficiency, resulting in decreased tenogenic properties in this region. Results of
this work provide insights into the key drivers of differential tissue phenotypes within
tendon, which furthers understanding of the factors most critical for tendon homeostasis.
3.2. Methods
Animal Use
Several mouse models were used in this study (IACUC approved). Scx-Cre
mice27 were crossed with Bgnf/f mice28 to generate a novel line of tendon-targeted
biglycan knockout mice. Cre-negative littermates were used as wild-type (WT) controls
60

for all experiments. Scx-Cre;Bgnf/f mice were further crossed with Scx-GFP29 or Col6a1GFP reporter mouse lines, resulting in fluorescent reporters for Scx+ and Col6a1+ cell
populations in biglycan knockout lines.
Gene Expression Analysis
WT and Scx-Cre;Bgnf/f mice (n=4-6/group) were used to analyze regional gene
expression in FDL tendons at P7, P14, and P21. For all gene expression analyses,
hindlimbs were degloved and fixed in RNase-clean 4% paraformaldehyde (PFA) for
three hours at 4⁰C immediately following moue euthanasia. After fixation, hindlimbs were
embedded and flash-frozen in OCT and stored at -80⁰C. FDL tendons were
cryosectioned at 20μm and maintained at -20⁰C or cooler to maintain RNA integrity.
Tensile and compressive regions were dissected from tendon sections using 25G
needles in an RNase-clean environment. The tensile region was defined as the tendon
region spanning proximal to the tibial notch (just proximal to the medial malleolus) up to
the myotendinous junction (Figure 3-1). The wrap-around region was defined as the
tendon region spanning distally from the medial malleolus to the sustentaculum tali.
While the wrap-around region is likely exposed to multi-axis, complex joint loads
including compression, we refer to this region as the “compressive” region for simplicity.
Dissected regions were digested with proteinase K, and RNA was extracted from these
samples (Zymo Quick-RNA Microprep). cDNA was reverse transcribed from template
RNA (Thermo High-Capacity cDNA RT) and was pre-amplified with Taqman probes for
target genes of subsequent analysis (Fluidigm Preamp Master Mix). For WT
experiments of regional PCM expression through postnatal development (Figures 3-2,3), polymerase-chain reaction (PCR) was performed (Thermo Taqman Fast Advanced
Master Mix) on pre-amplified cDNA with Taqman probes for Col6a(1-3), Bgn, and Abl1
(housekeeper). For gene expression analysis via Fluidigm PCR array (Figures 3-5,-6,-7,61

Figure 3-1. FDL tendon regions were defined by anatomical markers. The
tensile region (Tens) was defined as the FDL tendon region proximal to the
characteristic tibial notch up to the myotendinous junction. The compressive
region (Comp) was defined as the region spanning between the medial
malleolus and the sustentaculum tali.

8,-9), preamplified cDNA was loaded into a 96.96 GE Dynamic Array (Fluidigm) at the
Molecular Profiling Facility (University of Pennsylvania). ΔCt values for each gene were
calculated by subtracting Ct values of target genes from averaged Ct values of
housekeeper genes.
Collagen VI Staining and Fluorescent Reporter Imaging and Analysis
WT, Scx-GFP;Scx-Cre;Bgnf/f, and Col6a1-GFP;Scx-Cre;Bgnf/f mice (n=3-4/group)
were used to image collagen VI staining and fluorescent reporter populations at P7, P14,
and P21. At time of euthanasia, hindlimbs were degloved, fixed in 4% PFA for three
hours, and decalcified in 14% EDTA for 4-7 days (both at 4⁰C). After decalcification,
samples were washed in 1x phosphate buffered saline (PBS) for 1 hour at 4⁰C,
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embedded and flash frozen in OCT, and stored at -80⁰C. FDL tendons were sectioned at
8μm and stored at 4⁰C. Sections were glued with chitosan, dried overnight at room
temperature (RT), and stored at 4⁰C for later staining. Glued sections were washed in
PBS, blocked with 5% natural goat serum, and stained with anti-collagen VI rabbit 1⁰Ab
(Fitzgerald 70R-CR009X, 1:50 dilution) overnight at 4⁰C. Subsequent secondary staining
was performed with Alex 647 goat-anti rabbit 2⁰Ab (Thermo, 1:1000 dilution) for 1 hour
at RT, and sections were mounted with 1:1000 Hoescht stain in 50% glycerol. Hindlimbs
were imaged using a Zeiss Axioscan.Z1 with a 10x objective for DAPI, GFP, and Cy5
channels. Subsequent staining with toluidine blue was performed on select samples,
which were mounted with 30% fructose and imaged with a 10x brightfield objective.
To quantify collagen VI staining signal and GFP+ cell proportions, images were
exported, and ROIs for the tensile and compressive region were drawn in FIJI. ROIs
were applied to the Cy5 channel to quantify average collagen VI signal within each
sample region. To quantify GFP+ cell proportions, nuclei were segmented from DAPI
channel images and overlayed onto GFP channel images. GFP signal was thresholded
to numerate the percentage of GFP+ cells within each sample and region.
Mechanical Testing
FDL tendons from P14 and P21 WT and Scx-Cre;Bgnf/f mice (n=10/group) were
subjected to uniaxial viscoelastic mechanical tests as previously described.26 Following
euthanasia, intact mice were stored at -20⁰C for later testing. At the time of testing,
hindlimbs were dissected and FDL tendons were isolated from the hind foot. During
tendon isolation, the tensile/compressive region border was stained with Verhoeff’s
tissue stain to delineate each region ex situ. Tendons were fine dissected, and the
tensile/compressive region was demarked with Verhoeff’s stain beginning 0.5mm
proximal/distal to the region border and ending 1mm proximal/distal to this initial stain
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marker, respectively. Cross-sectional area (CSA) of each region was measured using a
custom laser device.30 Tendon edges were glued to sandpaper for testing grips, resulting
in a 4mm gauge length.
Tendons were immersed in a 1x PBS bath and loaded into an Instron. Instrons
were rigged with a cross-polarizer imaging setup to measure fiber realignment during the
mechanical tests.31 Samples were subjected to the following loading protocol: (1)
preconditioning (2) 1 minute rest (3) 3% stress relaxation for 10 minutes (4) 1 minute
rest (5) ramp to failure at 0.1% strain/sec. Stress relaxation, stiffness, and max load
were calculated from force-displacement data. Modulus, max stress, and realignment
were calculated based on optical tracking of regional stain lines and normalization to
sample CSA and gauge length using custom MATLAB programs.
Statistics
For experiments comparing regional WT properties (i.e., PCR gene expression
and collagen VI staining), paired t-tests evaluated potential differences between tensile
and regional values. For comparisons involving regional properties of WT and ScxCre;Bgnf/f tendons (i.e., Fluidigm gene expression, fluorescent cell proportions, and
linear modulus), two-way repeated measures ANOVAs with Sidak post-hoc comparisons
were performed to evaluate differences between tendon regions within genotype and
across genotypes within tendon region. To compare whole tendon properties of WT and
Scx-Cre;Bgnf/f mice (i.e, stress relaxation and stiffness), Students t-tests compared
properties across genotypes. Significance was set at p<0.05, and trends were set at
p<0.1.
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3.3. Results
3.3.1. Regional and Sex-Dependent Differences in PCM Expression Through Tendon
Development
To define the regional expression profile of key PCM molecules, we extracted
RNA from the tensile and the wrap-around, “compressive”, regions of the FDL tendon at
P7, P14, and P21. We measured the expression of genes encoding biglycan (Bgn) and
the three primary collagen VI alpha chains [Col6a(1-3)], which revealed significant
regional differences through development (Figure 3-2). At P7, expression of Col6a1
(trend) and Col6a2 was higher in the compressive region than the tensile region. At P14,
all four genes analyzed had higher expression in the compressive region compared to
the tensile region (Col6a1, trend). At P21, only Bgn saw trending increases in expression
in the compressive region compared to the tensile region.
Due to the large variability in P21 expression data, we stratified P21 samples by
sex and discovered sex-dependent expression changes at this age (Figure 3-3). While
male tendons demonstrated higher expression of Bgn, Col6a1, and Col6a2 in the

A
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Figure 3-2. Regional PCM expression peaks at P14. Expression of the three primary Col6
genes (A-C) and of Bgn (D) was higher in the compressive region compared to the tensile
region at P14. Most of these regional expression patterns were not present at P21. Solid lines
denote p<0.05, dashed lines indicate p<0.1.
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compressive region than that of the tensile region, this regional expression pattern was
not observed in female tendons. Instead, Col6a1 expression was heightened in the
tensile region compared to the compressive region.
3.3.2. Regional Differences in Collagen VI Content Through Tendon Development
We stained FDL tendon sections for collagen VI at P7, P14, and P21 to
determine if the regional differences observed in Col6 expression corresponded with
differential presence within the extracellular matrix. Signal quantification of collagen VI
immunofluorescence revealed regional differences in collagen VI presence through
development (Figure 3-4). Regional differences in collagen VI signal were not observed
at P7 (p=0.2). At P14 and P21, the compressive region contained higher collagen VI
stain than the tensile region. Collagen VI was more diffusive throughout the compressive
region matrix, while the tensile region contained more punctate staining.

Figure 3-3. Sex-dependent regional PCM expression is apparent at P21. While the
compressive regions of P21 male tendons had higher expression of Col6a1 (A), Col6a2 (B),
and Bgn (D), these regional differences were not present in P21 female tendons (or
reversed, for Col6a1). Col6a3 expression displayed no regional differences between sexes
(C). Solid lines denote p<0.05, dashed lines indicate p<0.1.
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Figure 3-4. Regional differences in collagen
VI content emerge at P14. While no regional
differences in collagen VI stain (pink) were
apparent at P7 (A), by P14 (B) the
compressive region contained increased
collagen VI compared to the tensile region.
This regional difference persisted at P21 (C).
Signal
quantification
revealed
these
differences were significant (D). Solid lines
denote p<0.05.
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3.3.3. Tendon Targeted-Biglycan Knockout and Distinct Regional Expression Profiles
through Tendon Development
To delineate the regional response of the FDL tendon to biglycan knockout, ScxCre mice were merged with Bgnf/f mice to generate a tendon-specific biglycan-null
mouse model (BgnKO). We confirmed biglycan knockout in tendon by measuring Bgn
expression at P7, P14, and P21 in both WT and BgnKO tendons (Figure 3-5). Due to the
sex-dependent expression differences observed at P21, this age group was stratified by
sex for this and all subsequent analysis. WT tendons displayed increased Bgn
expression in the compressive region compared to the tensile regions at all ages. In
BgnKO tendons, Bgn expression was significantly ablated compared to age-matched
WT tendons (13.1-49.1-fold reduction). No regional differences in Bgn expression were
observed within BgnKO tendons.

Figure 3-5. Bgn expression was severely ablated in BgnKO tendons. Bgn expression
was effectively knocked out in BgnKO tendons. WT tendons displayed increased Bgn
expression in the compressive region at all ages. Solid lines compare regions within a
genotype, while notched bars compare regions between genotypes. Solid lines denote
p<0.05.
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We sought to define the regional expression profiles of the FDL tendon at a
larger scale and to elucidate the effect of biglycan knockout on these regional properties.
We extracted RNA from WT and BgnKO tendons at P7, P14, and P21 and prepared the
samples for loading in a Fluidigm Dynamic Array. With this array, we measured the
expression of 96 genes through PCR, with target genes falling into categories of
collagens, non-collagenous matrix, pericellular matrix, matrix remodeling,
differentiation/cell markers, signaling, and housekeepers. Principal component analysis
(PCA) stratified the gene expression dataset by tendon region and age group (Figure 36). The tensile and compressive region had different principal component (PC) scores
across the primary axis, and within the two regions, each age group displayed different
scores from each other. PCA did not separate BgnKO tendons from WT tendons when
assessing the overall dataset.

Figure 3-6. PCA stratified gene expression data by tendon region and age. Grouped PCA
plots separated the tensile and compressive regions, as well as age within each region (A).
Values in axes labels represent the variance contributed to the overall dataset by each principal
component. Quantified PC1 scores revealed significant differences between regions and
across ages (B). Solid lines compare regions within a genotype, while notched bars compare
regions between genotypes. Solid lines denote p<0.05.
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We performed PCA on WT expression data to delineate the genes most
differentially expressed in either the tensile or compressive region. The genes most
enriched in the tensile region included Lox, Fbn1, Col12a1, Col2a1, Col14a1, Postn,
Col11a1, Col1a2, Col6a5, and Ltbp1. The genes most enriched in the compressive
region included Vcan, Sox9, Prg4, Fn1, Tgfb1, Bgn, Acan, Col5a1, Comp, and Mtor.
A clustered heatmap of the gene expression data revealed distinct gene clusters
with unique expression dynamics (Figure 3-7). This included groups of genes that were

Figure 3-7. Clustered heatmap reveals gene clusters with unique expression
dynamics. Like with PCA, a clustered heatmap of gene expression data stratified by region
and age (top two rows). Genes within the heatmap and clustered into groups with similar
regional and temporal expression dynamics. Clusters are labeled and further explained in
Table 3-1.
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highly expressed in the tensile region, those highly expressed in the compressive region,
and those that increased or decreased with postnatal age (Table 3-1).
Table 3-1. Expression Profiles of Gene Clusters

Cluster
Group

Expression Profile

Genes

1

Enriched in Tensile Region

Col1a1, Col1a2, Ltbp1, Fbn1, Lox

2

Enriched in Tensile Region,
Decreased Expression w/ Age

Col6a5, Mmp2, Tnc, Postn, Col14a1, Eln,
Mkx, Fbn2, Col11a1, Col2a1, Col12a1

3

Increased Expression w/ Age

Mmp3, Runx2, Mmp9, Mmp13,
Tgfb3, Dcn, Fmod, Col3a1, Tgfbr2

4

Enriched in Compressive Region,
Increased Expression w/ Age

Mtor, Sox9, Vcan, Tgfb2, Comp,
Col5a1, Prg4, Fn1, Tgfb1

5

Enriched in Compressive Region

Col6a2, Egr1, Acta2

6

Enriched in Compressive Region,
Decreased Expression w/ Age

Tnmd, Acan, Col6a3, Col6a1, Hspg2

3.3.4. Effect of Biglycan Knockout on Regional Gene Expression
While BgnKO tendons did not display array-level differences from WT tendons,
three genes were affected by biglycan knockout across multiple ages – Vcan, Mmp2,
and Col14a1 (Figure 3-8). Tendons from all groups displayed increased Vcan
expression in the compressive region compared to the tensile region. BgnKO tendons
had decreased Vcan expression compared to WT tendons in the compressive region at
P7 and P14 and in both regions in P21 male tendons. Mmp2 expression was increased
in the tensile region in WT P7 and P21 tendons. At these ages, both regions of BgnKO
tendons had increased Mmp2 expression compared to WT tendons, as well as
increased expression in the tensile region at P14. Tendons from all groups (aside from
BgnKO P7 tendons) had increased Col14a1 expression in the tensile region compared
to the compressive region. The tensile region of BgnKO tendons had trending increases
in Col14a1 expression compared to WT tendons at P7 and P21.
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Figure 3-8. Biglycan consistently altered
gene
expression.
BgnKO
tendons
displayed differences in expression of Vcan
(A), Mmp2 (B), and Cola14a1 (C). While
Vcan
was
downregulated
in
the
compressive region with biglycan knockout,
Mmp2 and Col14a1 were upregulated in the
compressive region. Solid lines compare
regions within a genotype, while notched
bars compare regions between genotypes.
Solid lines denote p<0.05, dashed lines
denote p<0.1.

In addition to genes that demonstrated consistent changes with biglycan
knockout, several genes were differentially regulated with biglycan knockout at P7 and in
P21 female tendons (Figure 3-9). At P7, both genotypes displayed higher expression of
Eln and Fbn1 in the tensile region compared to the compressive region. In BgnKO
tendons, the tensile region displayed decreased Fbn1 expression compared to that of
WT tendons, while BgnKO compressive regions had increased Eln expression. P21
female tendons had increased expression of Tnc, Postn, and Mmp3 expression in the
tensile region, while the compressive region had higher expression of Egr1. Within this
age and sex, BgnKO tendons had increased expression of Runx2 and Egr1 (both
regions), Tnc and Postn (compressive region only), and Mmp3 and Fn1 (tensile region
only).
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Figure 3-9. Biglycan altered expression of unique genes in P7 and P21 female
tendons. At P7, Eln expression (A) was upregulated in the compressive region of
BgnKO tendons, while Fbn1 expression (B) was downregulated in the tensile region of
these tendons. P21 BgnKO female tendons displayed changes in several genes (C-H)
compared to WT tendons. Solid lines compare regions within a genotype, while notched
bars compare regions between genotypes. Solid lines denote p<0.05, dashed lines
denote p<0.1.

3.3.5. Regional Differences in Cell Population and Matrix Properties Through
Development
To define the regional abundance of Scx+ and Col6a1+ cells, and how these
populations change with biglycan knockout, we crossed Scx-Cre;Bgnf/f mice with ScxGFP and Col6a1-GFP mice to produce two reporter lines with tendon-targeted biglycan
knockout. Quantification of both cell populations revealed unique regional proportions.
While no regional differences in Scx+ cell proportion was present at P7, a higher
proportion of Scx+ cells were present in the tensile region compared to the compressive
region at P14 and P21 (Figure 3-10). Despite these regional differences, Scx+ cells were
the predominant cell type in both regions, with proportions ranging between 80-95%

73

74

Figure 3-10. Scx+ cell populations were unaffected by biglycan knockout. Imaging of
collagen VI (pink) and ScxGFP (green) signal at P7 (A,B), P14 (C,D), and P21 (E,F) revealed
no qualitative differences in Scx+ cells in WT (A,C,E) or BgnKO (B,D,F) FDL tendons. Scx+
cells made up the majority of all cells within the FDL tendon. Tensile Scx+ cells had more
elongated nuclei, while compressive Scx+ cell nuclei were more rounded.

across both regions (Figure 3-11). Scx+ cells were uniformly dispersed throughout the
matrix. In all tendons except P21 BgnKO tendons, tensile Scx+ cell nuclei had lower
circularity than Scx+ cell nuclei in the compressive region, indicating that Scx+ tensile
cell nuclei were more elongated than Scx+ compressive cell nuclei.

Figure 3-11. The tensile region had a higher proportion of ScxGFP-positive
cells. While no regional differences in Scx+ cell proportion were observed at P7, at
later ages, this cell population was a higher percentage of overall cells in the tensile
region compared to the compressive region (A). Scx+ cell nuclei in the tensile region
had a lower circularity value than those cells in the compressive region (B). This
regional difference in nuclei circularity was not seen in P21 BgnKO tendons. A
circularity value of 1 indicates a perfect circle, while lower numbers indicate more
elongated ovals. Solid lines compare regions within a genotype. Solid lines denote
p<0.05, dashed lines denote p<0.1.

In Col6a1-GFP tendons, Col6a1+ cells were almost exclusively present in the
compressive region (Figure 3-12), with Col6a1+ cells making up <3% of all tensile region
cells (Figure 3-13). Col6a1+ cell abundance in the compressive region was maintained
around 15% through most of aging, although WT P14 tendons displayed a higher
proportion of Col6a1+ compressive cells (31%). Within the compressive region, Col6a1+
cells tended to localize deeper in the tendon, towards the ankle joint space. Col6a1+
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Figure 3-12. Col6a1+ cell populations were enriched in the compressive region but
unaffected by biglycan knockout. Imaging of collagen VI (pink) and Col6a1GFP (green)
signal at P7 (A,B), P14 (C,D), and P21 (E,F) revealed no qualitative differences in Col6a1+
cells in WT (A,C,E) or BgnKO (B,D,F) FDL tendons. While the tensile region was largely
devoid of Col6a1+ cells, these cells accounted for ~15% of all compressive region cells.
Within this region, Col6a1+ cells tended to localize in the deep tendon, close to the joint
space and contacts with the underlying bone.

compressive cells maintained a nuclei circularity comparable to that of Scx+
compressive cells. No differences in Scx+ or Col6a1+ cell proportion or nuclei circularity
were observed when comparing WT and BgnKO tendons.
In addition to defining cell population abundance, we defined the impact of
biglycan knockout on FDL tendon cellularity and regional collagen VI content (Figure 314). Cell density was highest at P7 (4100-4700 cells/mm2) and dropped at P14 (21002700 cells/mm2) and P21 (1200-2200 cells/mm2). The compressive region was more
cellular than the tensile region at all ages. No differences in cellularity were observed in
BgnKO tendons. Collagen VI regional content followed similar trends to previous results,

Figure 3-13. Col6a1+ cells were found almost exclusively in the compressive
region. While less than <3% of cells in the tensile were Col6a1+, over 15% of
compressive region cells were Col6a1+ across all ages. The nuclei of compressive
Col6a1+ cells were comparable to that of Scx+ cells in this region. A circularity value
of 1 indicates a perfect circle, while lower numbers indicate more elongated ovals.
Solid lines compare regions within a genotype. Solid lines denote p<0.05, dashed
lines denote p<0.1.
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with the compressive region containing higher staining signal than the tensile region at
all ages. No differences in collagen VI signal or qualitative staining were observed in
BgnKO tendons.

Figure 3-14. Biglycan knockout did not impact collagen VI presence or cell density.
Collagen VI staining was higher in the compressive region than the tensile region for both
genotypes at all ages (A). The compressive region was more cell dense than the tensile
region for both genotypes at all ages. Tendon cellularity dropped by nearly half between
P7 and P14. Solid lines compare regions within a genotype. Solid lines denote p<0.05,
dashed lines denote p<0.1.

3.3.6. Effect of Biglycan Knockout on Tendon Mechanical Properties
We subjected WT and BgnKO FDL tendons to uniaxial viscoelastic mechanical
tests to define the effect of biglycan knockout on tendon mechanical properties. Due to
size constraints and fragility of P7 FDL tendons, we used P14 and P21 tendons for this
analysis. P14 and P21 male BgnKO tendons displayed larger cross sectional-area in the
compressive region compared to the tensile region (Figure 3-15). P14 WT tendons
trended with this pattern as well. No differences in stress relaxation were observed
between genotypes at any timepoint. While P14 tendons did not display differences in
stiffness or max load across genotype, P21 BgnKO tendons displayed decreased
stiffness compared to WT tendons. P21 BgnKO female tendons also trended towards
decreased max load compared to time- and sex-matched WT tendons. P21 BgnKO male
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Figure 3-15. Biglycan knockout decreased tendon mechanical properties.
Compressive region CSA was higher than tensile region CSA at P14 (A). No differences in
stress relaxation were observed between genotypes (B). Stiffness was decreased in BgnKO
tendons at P21 (C). Max load was decreased in P21 female BgnKO tendons (D). Tensile
region linear modulus was decreased in P21 male tendons (E). No differences in max
stress were observed between genotypes. Solid lines compare regions within a genotype.
Solid lines denote p<0.05, dashed lines denote p<0.1.
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tendons displayed decreased tensile region modulus compared to P21 WT male
tendons. No differences were observed with max stress across genotypes. Realignment
patterns demonstrated the strain levels at which both tendon regions underwent
significant realignment (Figure 3-16). While most groups and regions underwent
realignment between1-3% strain, the tensile region of P21 BgnKO male tendons and the
compressive region of P14 tendons did not experience realignment between adjacent
strains.

Figure 3-16. Biglycan deficiency did not cause large changes in fiber realignment
patterns. Across most groups, the tensile (A-C) and compressive (D-F) regions realigned
early during ramp to failure (between 1-3% strain). The compressive region of P14 tendons
and the tensile region of BgnKO P21 male tendons did not experience realignment between
adjacent strains. Solid lines denote p<0.05, dashed lines denote p<0.1.

3.4. Discussion
This work revealed robust and distinct phenotypes between FDL tendon regions
during early postnatal development. These regional differences involved unique gene
expression signatures and differential PCM abundance. While biglycan knockout did not
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alter these regional properties at a large scale, biglycan deficiency impacted expression
of several genes and led to decreases in tendon mechanical properties.
In line with our hypothesis, the FDL tendon compressive region contained
increased expression and abundance of key PCM molecules compared to the tensile
region. The PCM is often associated with (fibro)chondrocytes,24,39 which rely on the PCM
in part as a stress shield against compressive loads.40 Given the compressive region
mimics a fibrocartilaginous matrix due to complex and compressive joint loads, cells
within this region likely rely on the PCM for similar stress-shielding purposes. Differential
PCM expression and abundance in this region became most apparent at P14 and
persisted through P21. Mice begin ambulating with more cage activity around two weeks
postnatal age.41 With increased movement comes increased hindlimb joint flexion, which
likely augments the joint forces experienced by the compressive FDL tendon region. The
corresponding emergence of differential PCM properties at this age provides further
evidence that complex and compressive joint forces cause the shift to fibrocartilaginous
phenotype in the compressive FDL tendon region.
Analysis of a larger panel of tendon- and cartilage- relevant genes revealed
further distinctions in expression profiles between the tensile and compressive FDL
tendon regions. Several genes enriched in the tensile region indicate enhanced
tenogenicity within this region, as Lox, Col1a2, Col11a1, Col12a1, and Col14a1 are
often associated with tendon matrix production and maintenance.42 Conversely, genes
enriched in the compressive region represent an increase in (fibro)cartilaginous
phenotype – Sox9, Acan, and Comp are essential genes in cartilage formation and
maintenance.43 Vcan and Bgn were also upregulated in the compressive region and are
linked to the PCM,31,44 further supporting increased PCM reliance within this region.
Surprisingly, Col2a1 expression was higher in the tensile region. Given collagen II is
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associated with a cartilaginous matrix,43 it is unclear why its expression is enriched in the
more tenogenic tensile region. However, evidence suggests that Col2a1 is a
mechanosensitive gene in tendon,45 thus increased expression of this gene in the tensile
region may be due to enhanced tendon loading with age.
Regional gene expression patterns coincided with differential abundance of key
cell populations across the two tendon regions. Scx+ cells were the primary cell
population in both regions, as expected based on previous studies using the Scx-GFP
reporter line.36,46 Decreased abundance of this cell population in the compressive region
suggests a decrease in the tenogenicity of native cells. The regional differences in Scx+
cell proportion were exacerbated with age, which supports the notion that joint forces
during hindlimb locomotion drive this differential cell phenotype. Scx+ cells also
displayed distinct nuclei circularity between the two regions, with tensile cell nuclei
appearing more elongated than compressive region counterparts. Since tenocytes are
often associated with spindle-like morphology compared to the rounded morphology of
(fibro)chondrocytes, this finding further validates decreased tenogenicity in the
compressive region. Col6a1+ cells were almost exclusively detected in the compressive
region compared to the tensile region. This result aligns with gene expression data
showing enhanced Col6a1 expression in this region and strengthens the model of
increased PCM production, presence, and reliance in the compressive region. The
dearth of Col6a1+ cells in the tensile region is surprising considering that collagen VI is
present within this regional matrix. It is unclear if the observed collagen VI presence in
the tensile matrix is “left-over” from production during earlier development, or if resident
cells maintain lower Col6a1 expression that does not trigger robust GFP signal.
Overall, gene expression and histologic data provide the strong conclusion that
compressive FDL tendon regions involve decreased cell and tissue tenogenicity
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compared to the tensile region. Reliance on collagen VI expression and production
further demonstrates that compressive region cells drift from a tenogenic to a
fibrocartilaginous phenotype.
While largescale changes in gene expression were not observed with biglycan
knockout, Vcan, Mmp2, and Col14a1 expression was consistently altered with biglycan
deficiency. Versican has been shown to impact musculoskeletal differentiation,47 and like
biglycan, versican localizes to the pericellular matrix and modulates TGF-β signaling.44,48
Given the overlap in roles and decreased Vcan expression in biglycan-null tendons,
versican and biglycan may interact within the PCM to regulate tissue properties. MMP-2
is a known matrix remodeller that is sensitive to mechanical loading and collagen VIdeficiency in tendon.49,50 Upregulation of Mmp2 in BgnKO tendons suggests that MMP-2
is impacted by biglycan presence and may result in increased remodelling in response to
biglycan knockout. Collagen XIV is a critical regulator of tendon collagen fibrils and colocalizes with biglycan in periodontal ligaments.51,52 Increased Col14a1 expression in
response to biglycan knockout provides further evidence that these molecules interact to
maintain collagenous tissue matrices. Overall, consistent expression changes of these
matrix molecules with biglycan knockout supports prior findings that demonstrate
interactions between these molecules. These interactions may serve as the key
mechanisms by which biglycan regulates tendon properties.
In addition to the consistent expression changes seen with Vcan, Mmp2, and
Col14a1, P7 and P21 female tendons displayed unique genetic responses to biglycan
knockout. At P7, Eln and Fbn1 were differentially regulated in biglycan-null tendons.
Elastin and fibrillin-1 both interact with biglycan to regulate tissue matrices, and results
here further support these interactions.53–55 P21 female tendons experienced unique
changes in several tendon genes with biglycan deficiency. Biglycan plays a role in the
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toll-like receptor (TLR) signaling pathway,56,57 and this pathway is differentially regulated
by sex.58,59 The unique expression changes in P21 female tendons seen here may be
due to divergence of male and female tendon signaling, especially TLR signaling, at this
age. This divergence may make female tendons more responsive to biglycan changes,
resulting in distinct changes in gene expression. Future research may define the sexdependent response to biglycan knockout at later postnatal ages. Such work may
provide further evidence of sex-dependent interactions between biglycan and TLR
signaling, which would reveal key insights into biglycan’s role in tendon.
In agreement with our hypothesis, most expression changes seen with biglycan
deficiency were observed in the compressive region, with less changes observed in the
tensile region. This may be expected due to enhanced Bgn expression in the
compressive region. Changes in this region seen with biglycan knockout could be due to
the compressive region being more sensitive and/or responsive to biglycan presence.
While biglycan deficiency in the FDL tendon resulted in consistent and unique
changes in gene expression, these expression changes did not correspond with
alterations to regional histologic tendon properties. Collagen VI staining and Col6a1+
cell proportions were unaffected by biglycan deficiency. This runs contrary to our
hypothesis and is surprising given the prevalent evidence that collagen VI and biglycan
interact within the PCM. With the expression changes seen in other PCM molecules with
biglycan knockout (i.e., Vcan and Fbn1), biglycan may regulate PCM properties without
directly regulating collagen VI expression or presence. Scx+ cell proportions were also
unaffected by biglycan knockout. This result was unexpected due to evidence that
biglycan augments tenocyte differentiation.8,60 Results here suggest that biglycan does
not directly impact cell tenogenicity.
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Despite lack of changes in PCM presence and cell population proportions,
biglycan-null tendons displayed decreased tendon mechanical properties. By P21,
BgnKO tendons were less stiff than WT tendons, and tensile modulus was diminished in
P21 male biglycan-null tendons. These results validate that biglycan impacts tendon
mechanics, which has been previously reported.11,61–64 While prior evidence suggests
that GAGs provide a structure-function role in tendon mechanics,65 the role of GAGs in
dictating quasi-static tendon properties remains disputed.66,67 Decreased mechanical
properties in BgnKO tendons may therefore be explained by a role of biglycan in
regulating the tendon collagen matrix, rather than biglycan directly impacting mechanics
through its GAG structure. This is supported by decreased collagen fibril size within
biglycan-deficient tendons,9 which may cause decreased mechanical properties. Altered
gene expression in the compressive region of biglycan-deficient tendons (noted above)
may protect the mechanical properties of this region to biglycan knockout, while the
tensile region does not compensate for biglycan knockout. Decreased mechanical
properties in the tensile region of biglycan-deficient tendons, coupled with a lack of
genetic response to biglycan knockout in this region, suggest that the tensile region is
more sensitive to biglycan presence. Future work may define regional fibril size
distributions to validate whether genetic changes in the compressive region protect the
matrix from fibril size perturbations and resulting reductions in mechanical properties.
While this study employed a holistic analysis to define the regulatory mechanism
of biglycan in dictating regional tendon properties, it is not without limitations. Although
changes in various genes were observed with biglycan knockout (Vcan, Mmp2, and
Col14a1), the proteins that these genes encode were not directly studied. This makes it
difficult to directly attribute the mechanical changes observed to altered gene
expression, as it is unknown whether these expression changes resulted in changes to
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functional protein levels. Further regulation of these molecules, including MMP-2, which
undergoes complex post-transcriptional processing,68 adds complexity to the potential
conclusions of this study. This study is also limited by the cell populations analyzed.
While no differences were observed in Scx-GFP and Col6a1-GFP reporter lines with
biglycan knockout, these are not the only distinct cell populations in tendon. It is possible
that biglycan alters the behavior of other tendon cell populations. For example, resident
tendon macrophages69 may be regulated by biglycan, as biglycan plays an important
role in inflammation. Future studies will provide targeted analysis of the molecules
shown to be differentially expressed with biglycan knockout, as well as analysis of other
cell populations within tendon. These studies will further refine the mechanism by which
biglycan regulates regional tendon properties.
This work demonstrates that distinct regions of the murine FDL tendon establish
unique tissue phenotypes during early postnatal development. These unique phenotypes
involve differential gene expression, PCM content, and cell population abundance.
Biglycan knockout impacts these regional properties through altered gene expression
and decreased tendon mechanical properties. Results provide deep understanding of
the phenotypic drift from tenogenicity to (fibro)chondrogenicity in tenocytes exposed to
complex joint loads. Biglycan regulation of tendon properties is also elucidated.
Understanding these key mechanisms of tendon homeostasis informs which factors are
most critical for preserving tendon health.
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS
4.1. Introduction
This dissertation delineated the role of biglycan and collagen VI in regulating
tendon function, defined the development of regional properties in the FDL tendon, and
elucidated the role of biglycan in regulating these regional properties, including
pericellular matrix (PCM) properties. In Chapter II, we employed multiple knockout
mouse models to define the coordinate roles of biglycan and collagen VI in regulating
FDL tendon properties. In Chapter III, we demonstrated the postnatal development of
distinct matrix regions within the FDL tendon, defined the regional activity of the PCM,
and detailed the impact of biglycan knockout on these regional tendon properties.
Conclusions from each chapter, and future directions for this work, are outlined within
this chapter.
4.2. Chapter II Conclusions
Tendon is a musculoskeletal tissue that is dependent on its aligned and highly
organized matrix for proper tissue function.1 Innumerable interactions between matrix
molecules help form and maintain this organized matrix,2 but this organization is lost in
tendon disease.3 Understanding the matrix interactions most critical for tendon health
would guide medical treatments for tendon disease and healing post-injury. Biglycan and
collagen VI are known tendon regulators,4,5 and evidence suggests that these molecules
interact to help form the pericellular matrix (PCM).6 Therefore, the objective of this study
was to delineate the coordinate roles of biglycan and collagen VI in regulating tendon
matrix and mechanical properties using single and combined knockout mouse models.
We hypothesized that both molecules would decrease tendon fibril size and mechanical
properties, that collagen VI knockout would result in more robust deficiencies than that of
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biglycan, and that knockout of both molecules would combine effects of each single
knockout for further reductions in tendon properties.
In line with our hypothesis, knockout of either biglycan or collagen VI led to
reductions in collagen fibril size and tendon mechanical properties. These changes were
more robust in collagen VI-null tendons than in biglycan-null tendons, indicating that
collagen VI is a stronger regulator of tendon properties. Contrary to our hypothesis,
knockout of both molecules did not lead to more severe deficiencies in tendon
properties. Instead, tendons deficient in both biglycan and collagen VI behaved similarly
to tendons from the single collagen VI knockout. This suggests that the tendon
regulatory roles of biglycan and collagen VI are not additive, and that these molecules
may have coordinate function in tendon.
This work provides unique insight into the mechanisms by which biglycan and
collagen VI regulate tendon function. Results support PCM models in which biglycan
organizes collagen VI microfibrils for proper PCM structure. Understanding the role of
these matrix molecules in tendon health is vital, as PCM components may be implicated
in the progression or prevention of tendon disease.7
4.3. Chapter III Conclusions
While tendon disease is marked by a disorganized and non-tenogenic matrix,
healthy tendon contexts also contain matrices with decreased tenogenicity. Tendons that
“wrap-around” joints display a fibrocartilaginous phenotype in the region that
experiences compressive joint forces.8 These wrap-around tendons provide a unique
model system in which the role of matrix molecules can be delineated across multiple
tendon loading environments. Such model systems can help further elucidate the
mechanosensitive mechanisms that govern tendon health. The PCM is also implicated in
these distinct matrix phenotypes, making it an interesting structure for regulating tendon
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function. Therefore, the objective of this study was to define the postnatal development
of unique FDL tendon regions, focusing on differential PCM properties of these regions,
and to elucidate the role of biglycan in regulating these regional tendon properties. We
hypothesized (1) that the wrap-around, “compressive”, tendon region would contain
heightened presence of PCM expression and protein compared to the normal, “tensile”,
tendon region and (2) that biglycan knockout would result in larger decreases in tendon
and PCM properties in the compressive region than in the tensile region.
In line with our hypothesis, PCM expression and presence was elevated in the
compressive region compared to the tensile region. The two regions also displayed
distinct expression profiles and housed differential proportions of Scx+ and Col6a1+
cells. Despite these differences and biglycan being highly expressed in the compressive
region, biglycan knockout did not lead to large changes in gene expression patterns,
collagen VI matrix presence, or cell population proportions. Several genes were
dysregulated with biglycan knockout, including genes encoding PCM and matrix
molecules with overlapping functions in tendon. As expected, biglycan knockout resulted
in decreased tendon mechanical properties. Unexpectedly, the tensile region displayed
decreased mechanical properties in biglycan-null tendons.
This work provides deep insight into the differential tissue phenotypes seen in the
FDL tendon during postnatal development. Results support prior literature that
demonstrates a fibrocartilaginous phenotype in wrap-around tendon regions and
validates that this phenotype is driven by compressive loads around the joint. Our gene
expression data further explains regional differences in phenotype, including enriched
expression of PCM and other cartilaginous genes in the compressive region. The lack
changes in collagen VI presence and Col6a1+ cell dynamics observed with biglycan
knockout challenges prior models in which biglycan regulates tendon properties through
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interactions with collagen VI. Results suggest a more direct role of biglycan in regulating
the tendon collagen matrix, while still implicating PCM molecules in these regulatory
mechanisms. Overall, this work provides defines the role of biglycan in dictating tendon
function and lays the groundwork for future studies on the regulation of key matrix
molecules in the development of regional tendon properties.
4.4. Overall Conclusions
Using various knockout mouse models and unique tendon model systems, this
dissertation defined biglycan regulation of tendon properties across distinct loading
environments and the extent to which this regulation involves the PCM. In defining these
regulatory mechanisms, we also provided novel insights into the development of regional
properties in wrap-around tendons.
We conclude that biglycan and collagen VI are both critical regulators of tendon
function and regulate tendon properties by modulating the native collagen matrix. While
biglycan may act through the PCM to achieve this regulation, results suggest that
biglycan does not substantially interact with collagen VI to maintain tendon function.
Instead, biglycan may be involved in direct organization of the tendon collagen matrix.
In addition to holistic analysis on the role of biglycan in tendon, this work was the
first to delineate the postnatal development of regional properties in a mouse wraparound tendon. While prior studies relied on larger animal models to characterize the
fibrocartilage region of wrap-around tendons, it was unknown whether this phenotype
was present in smaller animals such as mice. Results strongly support that these distinct
regional properties develop at an early postnatal age. With the accessibility of transgenic
mouse models, future work can leverage murine wrap-around tendons to further
elucidate the matrix structures most critical for proper tendon function.
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4.5. Future Directions
4.5.1. Further Investigation into Biglycan Regulation of Tendon Properties
While we elucidated the mechanisms of biglycan regulation in distinct tendon
regions, further refinement of this mechanism may be achieved. This work demonstrated
an important role of biglycan in regulating tendon mechanical properties, which supports
similar prior findings. Surprisingly, results of this study dispute prior models by which
biglycan organizes collagen VI within the tendon PCM to control tendon properties.
While PCM genes like Vcan were dysregulated in biglycan-null tendons, biglycan
deficiency did not impact collagen VI expression or matrix presence. It is possible that
biglycan still acts through the PCM to regulate tendon and that interactions with
molecules like versican are more essential to this regulation. Future studies may define
the effect of biglycan knockout on tendon PCM ultrastructure, on versican protein levels
and localization, and delineate the relative roles of biglycan and versican in regulating
tendon properties. Use of biglycan inducible knockdown models10 in this context, with
knockdown induced during tendon maturity, would define the direct role of biglycan in
tendon homeostasis without confounding effects of biglycan’s role in development. High
resolution imaging of the tendon PCM9 in biglycan-deficient tendons would test the
hypothesis that PCM organization is disrupted in the absence of biglycan, which would
support a PCM-organizing role of biglycan within tendon. Matrix localization analysis of
versican in biglycan-deficient tendons would test the hypothesis that versican protein
levels are diminished with biglycan knockout, which would suggest interactions between
these molecules. Future studies could then measure the tendon mechanical response to
versican and/or biglycan knockout to test the hypothesis that knockout of both molecules
results in more robust mechanical deficiencies than seen with single knockout of either
molecule. These results would elucidate potential coordinate roles between biglycan and
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versican within the tendon PCM. Understanding the specific mechanism of biglycan
regulation in tendon is critical given the implication of biglycan in tendon disease.11,12
4.5.2. Defining Interplay between Distinct Cell Populations
Although this study employed novel analyses to distinguish regional proportions
of distinct cell populations, more insights can be drawn from the interplay between cell
types and how cellular communication results in different matrix phenotypes. Regional
Col6a1+ cell proportions were inversely correlated with those of Scx+ cells, as Col6a1+
cells were primarily in the compressive region, where Scx+ cells were less abundant.
This suggests reciprocity between these cell populations, where excessive Col6a1
expression may drive suppressed tenogenicity. These relationships could be further
elucidated through co-culture of Scx+ and Col6a1+ cells and measurement of resulting
tenogenic gene expression.13 This analysis would test the hypothesis that Col6a1+ cells
signal tendon lineage cells to dampen tenogenic gene expression. Such research would
provide unique insights into crosstalk between distinct tendon cell populations and would
implicate collagen VI production as a negative regulator of tenogenicity.
Populations such as resident tendon macrophages, Tppp3+ cells, Axin2+ cells,
and αSMA+ cells have gained recent interest due to suggested roles in tendon.14–17
Defining the regional activity of these cell types with fluorescent reporter lines may
reveal key aspects of these populations and how they regulate tendon function. If
regional differences in these cell populations were discovered, those cell populations
may also be implicated in augmenting or suppressing native tenogenicity and could be
tested with similar co-culture techniques. For example, it may be hypothesized that cell
types associated with tendon stem cells (i.e., Tppp3+ or Axin2+ cells) are enriched in the
tensile region compared to the compressive region. If this is found to be true, coculturing these cell types with Scx+ cells would test the hypothesis that these “tendon
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stem cell” types enhance tenogenic gene expression in Scx+ cells. Such results would
implicate those tenogenic-enhancing cells as critical for maintaining tendon phenotype
and would motivate these tendon stem cell populations as targets for disease treatment
paradigms.
4.5.3. Deeper Analysis of Distinct Tendon Regions
In addition to cellular analyses, further matrix analyses may provide additional
understanding of the initiating factors that differentiate the tensile and compressive
region. The objective of such work would be to delineate whether resident cells or the
tissue matrix first differentiate the regional properties of wrap-around tendons. Imaging
the matrix regions with stains such as picrosirius red18 would define the relative collagen
organization of each tendon region and how that organization changes with development
and aging. AFM microindentation19 and fibril mapping20 would provide matrix
compressive mechanical properties and higher resolution collagen fibril images.
Collagen cross-linking assays21 can be used to determine differences in collagen fibrils
regulation between the two regions. By tracking matrix properties through postnatal
development, these analyses would give insight into the matrix microenvironment in
which native cells reside and inform how these distinct environments drive the regional
cell behavior observed in this work. Such work would test the hypothesis that the
compressive region contains decreased organization and cross-linking, with increased
compressive mechanical properties, and that regional cell behavior (i.e., gene
expression and cell population abundance) is altered prior to changes in the surrounding
tendon matrix. This hypothesis would implicate cell-intrinsic mechanisms in balancing
tenogenicity, rather than changes in tendon matrix preceding and driving cellular
phenotype. Understanding the relationship between matrix environment and cell
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tenogenicity can inform therapies and strategies to recapitulate a healthy tendon
environment.
4.5.4. Inducing a More Extreme Loading Spectrum
Wrap-around tendons may be further leveraged to gain insight into the
mechanosensitive mechanisms that drive tenocyte biology. Compressive forces are
known to cause the fibrocartilage phenotype within wrap-around tendons - a discovery
that contributed to early understanding of tenocyte mechanosensitivity.22 Additional
research defined the dynamic response of tenocytes loading spectra in explant contexts,
demonstrating the sensitivity of tenocytes to proper tensile forces.23 While other ex vivo
constructs have replicated specific aspects of collagen fibrillogenesis,24 tendon explants
are preferred as they house all native tendon matrix proteins and therefore model the
complex molecular interactions within the tendon matrix. Such explant systems could be
leveraged with the current use of wrap-around tendons and knockout models to define
the mechanosensitive response of matrix molecules in a more controlled manner. For
example, biglycan-deficient tendon explants may be exposed to excessive
compressive22 or tensile forces,25 and the response of the tensile and compressive
region could be delineated. This analysis would test the hypothesis that tendons are
more sensitive to biglycan-deficiency in contexts of excessive tissue loads. Such
knowledge would inform the tissue states most vulnerable to degeneration (i.e., an
underloaded biglycan-deficient tendon may not degenerate quickly, but an overused
biglycan-deficient tendon may rapidly degenerate). Researching these
mechanosensitive mechanisms in a controlled explant environment would elucidate the
specific roles of matrix molecules in regulating tenogenicity.
Techniques like mouse treadmill running26 and botox27 injections have also
provided insight into the in vivo tenocyte response to varied loads. Use of these load102

modulating techniques may be critical for understanding regional differences in murine
wrap-around tendons. Prior studies characterizing the regional properties of FDL
tendons used larger animal models, such as bovine28 and canine29, in which larger joint
loads are imparted on the wrap-around region than those experienced in murine joints.
These larger joint loads likely produce a more divergent phenotype within the wraparound region. Therefore, mouse treadmill running may be used to elicit a more robust
regional phenotype like those seen in larger animal models. By analyzing FDL tendon
gene and mechanical properties in response to loading (with treadmill running) or
unloading (via botox injections to calf muscles), the mechanosensitivity of the tensile and
compressive region could be delineated. Such work would test the hypothesis that the
tensile region is more sensitive to unloading while the compressive region is more
sensitive to overloading, resulting in decreased tenogenic gene expression and
mechanical properties for each region under those respective loading states. These
findings would augment the understanding of how tenocytes respond to a wide range of
loadings and would incorporate systemic effects that would not be accounted for with
explant studies. Such understanding would inform efforts in recapitulating healthy tendon
loads, whether in tendon disease treatment or the production of tissue engineering
constructs.
4.5.5. Defining the Regional Role of Other Key Matrix Molecules
While this study focused on biglycan, other matrix molecules have been shown to
be critical tendon regulators as well. Many lower abundance matrix proteins (LAMPs)
have demonstrated a role in regulating the tendon matrix, such as decorin, fibromodulin,
lumican, and various collagens (V, XI, XII, XIV).32–36 While some of these molecules also
have known roles in cartilage,37–39 their differential role in compressive region
fibrocartilage remains unknown. Similar analysis to that employed in this work could
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define the regional role of key tendon molecules and elucidate the mechanisms by which
they regulate tendon function. This may include targeted analyses of known interacting
partners, such as collagen I, aggrecan, or collagen VI.40–42 For example, collagen V’s
dual role in tendon and cartilage may be studied using wrap-around tendons. The
hypothesis that collagen V is more critical for maintaining tenogenicity than
chondrogenicity could be tested by analyzing the regional response of FDL tendons to
collagen V knockout. Understanding the multiple roles of these molecules in different
tissue contexts would provide insight into the stimuli and factors most essential for
tendon homeostasis.
4.5.6. Comparisons to Clinically Relevant Tendon Fibrocartilage Contexts
Outside of wrap-around tendons, other tendon contexts contain fibrocartilage of
clinical interest – the enthesis and the Achilles calcaneal insertion. The enthesis is a
tissue spectrum at the tendon-bone attachment that ranges between bone, mineralized
fibrocartilage, unmineralized fibrocartilage, and tendon within a few millimeters41. The
enthesis is commonly injured in tendons like the supraspinatus and is therefore
extensively studied.42 Recent research has defined the cellular lineage of resident
fibrochondrocytes and how they interact with native tenocytes at this tissue border. 43 The
Achilles calcaneal insertion is a common site of pain and tendon disorder, giving it
clinical interest of study.44 This region develops fibrocartilage in response to
compressive forces from wrapping around the calcaneus. It is unknown whether
compressive region fibrocartilage in the FDL tendon is similar to or distinct from these
other tendon fibrocartilage contexts. Employing a holistic analysis, as performed in this
work, on the expression profiles and cell populations present in these different regions
would test the hypothesis that these fibrocartilage regions contain similar tissue
phenotypes to one another.
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If these distinct fibrocartilage contexts contain similar gene expression and cell
population properties, wrap-around tendons could serve as an isolated model system in
which tendon fibrochondrocytes can be studied. This would diminish the potential
confounding effects of studying directly at the enthesis or calcaneal insertion, such as
crosstalk with osteo-lineage cells.45 Researching the fibrochondrogenic drift of tenocytes
in an isolated environment would provide fundamental understanding of the mechanisms
most critical for preserving or changing tendon cell fate. This knowledge may be
leveraged across a wide range of contexts, such as disease prevention, enthesis
regeneration, or calcaneal tendinopathy therapies. Therapies aimed at restoring
tenogenicity, such as scaffolds and growth factors,46 could be tested on compressive
fibrocartilage to determine whether the therapy effectively preserves a native tendon
phenotype.
If differences are discovered between fibrocartilage of wrap-around tendons, the
enthesis, and the calcaneal insertion, these differences may also be leveraged for
clinical significance. Wrap-around tendons exist in homeostasis and are not as prone to
degeneration or injury as the supraspinatus enthesis or the calcaneal insertions. Thus,
uncovering the differences in resident cells and matrix content between these distinct
fibrocartilage regions would delineate the factors that may cause or prevent
degeneration and injury.
4.5.7. Regional Response to Tendon Injury
The regional injury response of wrap-around tendons has not been defined and
may provide insight into the key factors of successful tendon healing. Like most flexor
tendons, the FDL tendon contains a sheath. This sheath complicates the normal tendon
healing process, as adhesions form with the surrounding connective tissue, resulting in
decreased range of motion and function.47 Flexor tendon healing has thus been studied
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extensively, and the FDL tendon has been used as a model system for tenocyte healing
processes.48,49 These studies, however, did not exploit the distinct compressive and
tensile regions and their potentially unique responses to tendon injury. By performing
transections through the compressive or tensile region and measuring the resulting gene
expression and mechanical properties through healing, the differential healing response
of each region may be contrasted. This study would test the hypothesis that enhanced
loading in the compressive region (via joint flexion) delays the early tendon healing
response, resulting in inferior healing outcomes. Regional healing outcomes could then
be correlated to the phenotypic differences seen between regions, and the factors most
critical for successful healing outcomes could be identified. Further, the non-transected
region could be studied as a model system of matrix remodelling (i.e., the tensile region
with compressive region transection or vice versa). This would provide additional insight
into the regional response to unloading, as the down- or up-stream transection would
reduce the load experienced by the non-injured region. This added experimental
condition could test the hypothesis that the compressive region is more sensitive to
unloading due to higher loads experienced by this region compared to the tensile region
during normal joint loading. Overall, wrap-around tendons possess untapped potential as
model systems for understanding tendon healing under diverse loading conditions.
4.5.8. Sophisticated Mechanical Analysis of Regional Tendon Properties
While this study employed viscoelastic tensile tests to delineate the mechanical
properties of WT and biglycan-null tendons, we did not find regional differences in WT
modulus. This is surprising given the diminished tenogenicity in the compressive region,
which would suggest decreased tensile properties compared to the highly tenogenic
tensile region. Sophisticated mechanical analyses, such as dynamic sweeps or fatigue
testing,46,47 could extract key mechanical properties outside of the quasi-static and
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viscoelastic parameters measured in this study. Results of dynamic sweeps and fatigue
tests, such as dynamic modulus, phase shift, fatigue life, and laxity, would test the
hypothesis that the tensile region maintains tissue properties through repetitive load,
while the compressive region loses mechanical integrity with repetitive load. These
mechanical parameters would likely uncover the key functional differences between the
compressive and tensile tendon regions. These differences could be compared to the
different matrix environments of each region, which would define structure-function
relationships of these differential matrix components. For example, if compressive
fatigue properties were inferior to those of the tensile region, these decreased
mechanical properties could be attributed to increased GAG content in the compressive
region. Knowledge of these structure-function relationships is critical for efforts like
tissue engineering design.48
4.5.9. Regional Property Divergence with Age
While this work identified key properties that distinguish the tensile and
compressive region, the scope of this work was limited to postnatal mice. The
fibrocartilage phenotype in the compressive region is exacerbated with age.28 Thus, the
distinct tendon regions may drift further in tissue phenotype from each other. Studying
this temporal relationship through gene expression, cell population, and matrix analysis
may uncover the factors and stimuli that maintain tenogenicity and those that cause the
shift to fibrochondrogenicity. This analysis would test the hypothesis that tendon aging
factors cause further divergence of regional phenotypes. Treating these wrap-around
tendons with anti-aging therapies like blood exchange53 and measuring gene
expression and mechanical properties in response would further test the hypothesis that
age-related changes in regional tendon phenotypes are reversible with anti-aging
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therapies. Identifying these regulatory factors would be impactful for therapies to prevent
deleterious tendon aging processes.
4.5.10. Sex-Dependent Regional Properties and Divergence with Age
One surprising finding of this work was the sex-dependent expression patterns
observed at P21. While tendons exhibit sex-dependent differences,54,55 it was unknown
whether these differences would manifest in tendon at this early postnatal age. Female
P21 tendons also exhibited a unique expression response to biglycan knockout, further
implicating sex differences in driving differential tendon function. It is unknown, however,
if the early sex-dependent gene expression observed here would propagate to functional
differences in the tendon matrix. Further research should therefore define the temporal
dynamics that sex imparts on the regional matrix content and mechanical properties of
wrap-around tendons. Such work would test the hypothesis that males experience more
fibrochondrogenic drift in the compressive tendon matrix compared females. In this case,
the factors that distinguish these sex-dependent differences would be implicated as
important drivers of tendon cell fate.
Future work may also define the sex-dependent effect of biglycan knockout on
these regional properties at later mature ages. By measuring further alterations in gene
expression, differences in matrix content, and the resulting tendon mechanical
properties, interactions between biglycan and sex-dependent tendon signaling may be
elucidated. This would test the hypothesis that biglycan interacts with sex-regulated
signaling pathways, resulting in female tendons compensating for biglycan deficiency
and protecting them against decreases in tenogenicity that are present in male, biglycandeficient tendons.
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4.6. Final Conclusions
This dissertation provided unique insight into the mechanisms by which biglycan
regulates regional properties of wrap-around tendons and its potential involvement in the
pericellular matrix. In doing so, we defined the postnatal development of robust regional
differences within tendon tissue. This work lays the foundation for future research into
the matrix structures that maintain or degenerate native tenogenicity. Understanding the
structures and factors most essential to balancing tissue phenotype would inform all
efforts that aim to preserve tendon health and function.
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APPENDIX A: Mouse FDL Dissection and Prep
Dissection
Materials:
1x PBS
Dissection Tools (Fine forceps, #3 Blade Holder, #11 Blades, Microscissors)
Weigh boats (or any small container to hold specimens)
Plastic specimen bags (for extra tendons, if needed)
Gauze
Rubber Mat
Dissection Microscope (sign up on google calendar!)
Method:
1. Thaw mouse in warm water for approximately 30 minutes.
2. Label one weigh boat per tendon.
3. Remove skin from hindlimb.
a. Make incision through skin near the knee, cut around the leg to
disconnect all distal skin
b. Peel loose skin towards the foot, remove what is easily ripped off.
c. Cut off toes close to their base.
d. Make longitudinal incision down the top of the foot, deglove remaining
skin.
4. Remove muscle superficial to FDL tendon with forceps.
5. Slide forceps underneath FDL tendon, slide distally to disconnect tendon from
foot insertion.
6. Thread forceps between FDL tendon and FHL tendon, slide distally to
disconnect the tendons.
a. FDL wraps medial to the calcaneus, FHL tendon wraps on top of
calcaneus
7. Tease FDL tendon out of superficial muscle until the tendon is separated
from the bottom of the foot.
8. With hands, pull FDL tendon distally to pull apart from myotendinous junction.
Place in PBS.
a. Note: Steps 3-8 outlined in video under
\maxine\soslowskylab\Protocols\Knee and Supra Dissection
9. Remove any other desired tendons (Achilles, patellar, etc.)
10. Scrape off excess muscle, loose connective tissue from FDL tendon using
forceps.
11. Cut and pull off tendon sheath using microscissors and forceps.
a. Tendon sheath spans the short length of FDL tendon that wraps
around the ankle.
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Stain Line Application
Materials:
Verhoeff Stain (Recipe included)
Kimwipe
Ruler
Stain Line Suture
Dental wax
Verhoeff’s stain recipe: Combine solution A:B:C in a 2:1:1 ratio. Only make enough to
use that day in a small weigh boat. Do this about 30 minutes before you want to stain.
Put stain line suture in the solution to coat.
Method:
1. Build custom ruler setup out of wax pieces and your ruler.
2. Blot tendon dry with Kimwipe, line up tendon with ruler.
3. Starting at the point just proximal to digit branching, apply stain lines at 0,
1.25, 3.75, and 5 mm.
a. One side of the FDL tendon has a midline trough, the other has a
triangular trough near the digit branching (pictured on next page). This
triangular trough is a good landmark for consistent identification of
“branching point”.
4. Blot excess ink dry. Place back in PBS.
Area Measurement
Materials:
GisMO (Sign up on google calendar!)
Labview 2013
Kim Wipes
Fine Forceps
Method:
1.
2.
3.
4.

Uncover GisMO and turn on laser (~10 minutes in advance).
Open National Instruments Labview 2013. You will see this screen:
Open ‘mogware.vi’.
Prepare tendon, program for measurement.
a. Dab tendon dry on Kimwipe.
b. Lay tendon flat on stage so that tendon is parallel to stage edges.
c. Line up laser on first stain line.
d. Click ‘Run’ (top left corner), ‘Start’, ‘Capture Mode’, ‘Zero’ all 3 axes.
5. Turn black wheel to scan across tendon width. Tendon height will be
apparent on thickness plot.
6. Turn blue wheel to move stage 0.5mm in y direction (about 2 full turns).
7. Repeat steps 5&6 until you have covered tendon length that is stained (5mm,
11 passes).
8. Click ‘Stop’.
9. Replace tendon in PBS bath.
10. Save file, turn off Capture Mode.
11. Double check that the file shows all values being zeroed and that
measurements were collected.
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12. Repeat steps 4-11 for remaining samples.
13. Close software, log off computer, turn off laser, cover GisMO.
Sandpapering
Materials:
400-Grit Sandpaper
Scissors
Dental Wax
Superglue
Forceps
Kimwipe
Method:
1. Cut sandpaper into pieces approximately 10x5mm.
2. Lay two pieces of sandpaper grit side up and apply thin layer of super glue to
each.
3. Dry tendon on Kimwipe.
4. Using forceps, carefully lay distal side of tendon onto sandpaper so that the
most distal stain line lines up with edge of sandpaper (image below).
5. Place small drop(s) of super glue onto portion of tendon within sandpaper.
6. Place other sandpaper piece on top of tendon and sandpaper, press firmly
with forceps handle for ~20 seconds.
7. Rehydrate in PBS, repeat for proximal side of tendon.
Note: Glue may leak out of sandpaper sandwich during pressing. Check
under stereomicroscope to see if glue is stuck to tendon near sandpaper.
Glue can be pulled away (carefully) with forceps.
Note: Proximal side of sandpapered tendon should be apparent due to
overhanging tendon. If not apparent, be sure to mark sandpaper with Sharpie
to differentiate proximal vs distal side.
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APPENDIX B: Mouse FDL Mechanical Testing
Materials
Instron 5542
Instron Computer (Runs Bluehill 3 Software)
Imaging Computer
50N Load Cell
Tank + Accessories (pictured below)
1x PBS
Hex Key
Camera + Accessories (pictured below)
Cross Polarizer + Accessories (pictured on next page)
Method
Setup Instron, Camera, and Software
1. Screw 50N load cell in to crosshead, plug into Instron.
2. Screw stage to the Instron base with hex keys. Dovetail stage in tank should
be away from Instron.
3. Turn on Instron and log into corresponding computer. Open Bluehill 3
software.
4. Calibrate the load cell. Click on load cell icon and click ‘Calibrate’ (pictured
below).
5. Click ‘Test’. Open protocol: Mouse_FDL_5mm_gauge
a. 10 cycles of preconditioning (0.01-0.02N at 1Hz)
b. Rest for 5 minutes
c. 5% stress relaxation (0.25mm, 5%/s, equilibrate for 10 minutes)
d. Rest for 1 minute
e. Ramp to failure (0.5%/s)
6. Ensure file is saved to proper location. Click next.
7. Log into imaging computer. Open NI MAX software and National Instruments
Labview 2013.
8. In NI MAX, open camera (‘Devices and Interfaces’→NI-IMAQ
devices→camera0)
9. Plug data acquisition device (DAQ) input into Instron (pictured on next page).
10. Plug DAQ output and motor control input into corresponding USB ports on
imaging computer (pictured on next page).
11. Open CIMM Ware in Labview. Change camera to cam0. Ensure that trigger
threshold is set at 3V.
12. Prepare Sample
12. Clamp tendon between two clamps.
13. Note: One clamp is suited for the bottom dovetail (in the tank). This clamp
has teeth across the top piece (pictured below). Use this clamp for the distal
portion of the tendon.
a. Line up edge of sandpaper with edge of clamp.
b. Tighten screws until finger-tight.
c. Repeat for the proximal portion.
14. Slide bottom clamp (w/ distal tendon end) into tank dovetail.
15. Attach dovetail jig to load cell with pin, tighten.
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a. Ensure dovetail axis is parallel with edge of tank.
16. Slide top clamp (w/ proximal tendon end) into dovetail jig. Adjust tank stage
as needed.
Collect Pretest Image
17. Turn on light and set intensity at about half of max.
18. Adjust camera height, position, and focus to ensure view of tendon.
19. Balance load cell while tendon is slacked.
20. Align tendon visually (use force valleys to fine tune alignment).
21. Load tendon to 0.01N, reset displacement.
22. Take pre-test image. Save as “Sample ID_pretest” under appropriate folder.
Click out of ‘Camera’ in NI MAX (otherwise CIMM Ware won’t run).
23. Unload tendon.
Begin Test
24. Place crossed polarizer on the Instron base using metal clamp. Keep axle
about 2mm away from tank wall. Plug motor control cord into crossed
polarizer. DO NOT TOUCH OR BUMP WHEELS.
25. Position the polarizer divot at the top of the wheel for “zero angle” state.
26. In CIMM Ware, ensure the images are saved to the proper folder with proper
sample name.
27. Run CIMM Ware.
28. Refocus camera.
29. In CIMM Ware, click ‘Zero Angle’ and ‘Motor Start’.
30. Balance load cell.
31. Bring tendon to zero displacement (should be about 0.01N).
32. Begin test in Bluehill 3.
33. Set timer for 16 minutes. This will give you time to get back for ramp to
failure.
34. When ramp to failure is about to begin (1 minute after stress relaxation), set
CIMM Ware trigger threshold to -1V.
35. Upon failure, reset CIMM Ware trigger threshold to 3V. Stop test.
36. Manually jog up to move upper clamp away.
Collect Scale Image
37. Reopen camera in NI MAX.
38. Take image of ruler.
a. Ensure ruler is in plane with failed tendon.
b. Save as “Sample ID_gauge’.
39. Ready to set up next specimen.
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APPENDIX C: Scx-GFP Genotyping
Objective: Image tail tips for green fluorescence to genotype Scx-GFP mice
Materials:
- Tail tip scissors
- Eppendorf tubes
- Gauze
- Silver nitrate sticks
- DI Water
- Fine forceps
- Plastic Petri dish (grid labeled)
- 1X PBS
- Zeiss Axio Zoom.V16
Procedure:
1. Label Eppendorf tubes for each mouse ID
2. Tail tip mice
a. Ear tag as needed
b. Snip <5mm tail tip and collect in Eppendorf tube
i. Younger mice (~P7) require larger tail tip, but still should be <5mm
c. Clot tail with gauze and silver nitrate sticks if necessary
d. Wash scissors in DI water between mice
i. More important for DNA genotyping, water elutes nucleic acids
3. Turn on Axio Zoom bulbs/light sources
a. Bulbs/light sources should be labeled 1, 2, 3, turn on in that order
i. 1: HXP 200C, 2: EMS3
ii. Do not need 3rd bulb (ApoTome.2)
b. Allows for warm up time during dissection
4. Dissect tail tips
a. Transfer tail tip into PBS bubble within grid-labeled Petri dish
b. Remove outer skin and expose inner tail tip
i. Method 1: Squeeze distal end of tail tip until inner tip pops out
from skin
ii. Method 2: Use forceps to cut open tail tip along its side and
remove inner tail tip
c. Make note of each sample location within grid
5. Image tail tips for GFP fluorescence
a. Turn on Zen software and image acquisition mode (“Zen Pro”)
b. If minimized, expand Motorized Zoom by clicking the object within
“Microscope Control”
c. Switch to Acquisition Mode and select profile with GFP filter
d. Switch to Live imaging
e. Move stage to center sample
i. Bright Ring imaging
ii. X-Y controls are manual wheels
iii. Focus control is Ctrl + Alt + mouse scroll (+ Shift for faster focus)
iv. “Best Fit” in display settings auto-adjusts intensity
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f.

Image for fluorescence
i. Zoom to ~6x
ii. Switch to GFP filter
iii. Auto-adjust intensity
1. GFP+ tips will have green fluorescent signal in tail
tendons, IVD
g. Note if sample is positive, repeat for other tips
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APPENDIX D: EDTA Solution Preparation
Objective: Prepare 1L of 14% wt/vol EDTA solution to use as a decalcifying agent for
histological samples
Materials:
- 1L Flask
- pH Meter
- Scale
- Magnetic Stir Plate + Bar
- DI Water
- EDTA Powder
- Ammonium Hydroxide
Procedure:
1. Calibrate pH meter (follow manufacturer’s protocol)
a. Briefly, rinse probe in DI water after immersion in each calibration solution
b. Immerse probe in calibration solutions (pH=7, 4, 10)
2. Pour 750mL of DI water into 1L flask on stir plate with stir bar
3. Weigh out 140g of EDTA powder and pour into flask
4. Measure 90mL of ammonium hydroxide and slowly pour into 1L flask
a. Periodically measure pH with pH meter
5. Titrate solution until pH~7.1
a. May need extra EDTA or ammonium hydroxide
6. Allow EDTA to dissolve via stir bar
a. Will change from white, insoluble precipitate to yellowish liquid with
addition of ammonium hydroxide
7. Add DI water until 1L of total volume
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APPENDIX E: Hindlimb Fixation (Histology)
Objective: Fix and decalcify FDL tendon and surrounding tissue for histologic imaging
Materials:
- Scalpel holder + #11 scalpel blades
- Fine forceps
- Falcon tubes (10mL for P7, P14 mice, 50mL for P21 mice)
- 10X PBS, Nuclease-free (Invitrogen #AM9625)
- Water, Nuclease-free (Fisher #BP561-1)
- 32% PFA, EM grade (EMS, #15714-S)
- 14% EDTA solution (see corresponding protocol)
- 1x PBS
- 2-Methylbutane
- Dry Ice
- Kimwipes
- OCT Embedding medium
- Embedding molds, 24 x 24 x 5mm
Procedure:
1. On day of harvest, prepare fresh 4% PFA fixative solution
a. For P7 and P14 mice, prepare 10mL by combining:
i. 1mL 10x PBS
ii. 7.75mL Water
iii. 1.25mL PFA (in hood)
b. For P21 mice, prepare 30mL by combining:
i. 3mL 10x PBS
ii. 23.25mL Water
iii. 3.75mL PFA (in hood)
2. Properly sacrifice mice
a. For <P14 mice, secondary confirmation (decapitation) required
3. Dissect hindlimbs with scalpel and forceps
a. Cut off limb at knee
b. Slice skin down front of shin and foot
c. Deglove hindlimb, leaving skin on toes (will preserve tendon insertion +
tension)
4. Place hindlimbs in PFA solution
a. Ensure ankle is flexed slightly obtuse to 90⁰
5. Incubate hindlimbs in solution for 3hr at 4⁰C
6. Prepare 1% PFA in EDTA decalcifying solution
a. For P7 and P14 mice, prepare 10mL by combining:
i. 10mL EDTA
ii. 0.32mL PFA
b. For P21 mice, prepare 30mL by combining:
i. 29mL EDTA
ii. 1mL PFA
7. After 3hr fixation, cut toes off hindlimb and remove remaining skin
8. Place hindlimb in decalcifying solution, incubate at 4⁰C for several days
a. For P7 mice, allow 3-5 days for proper decalcification
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b. For P14 and P21 mice, allow 5-7 days for proper decalcification
9. On day of embedding, incubate hindlimb in 1xPBS at 4⁰C for 1hr
10. 15min prior to embedding, cool 2-methylbutane with dry ice
11. Embed hindlimbs
a. Dry off hindlimbs with Kimwipe
b. Coat bottom of embedding mold with OCT
c. Orient hindlimbs within mold
i. User preference, lateral side down
ii. Best for sectioning if calcaneus is pressed to mold bottom
d. Coat samples in OCT
12. Freeze embedded samples in 2-methylbutane
a. Only immerse mold bottom and allow bottom OCT layer to freeze
b. Plunge rest of mold in 2-methylbutane, let freeze for at least 1min
13. Store at -80⁰C for future sectioning
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APPENDIX F: Hindlimb Fixation (Needle Capture Gene Expression)

Objective: Fix FDL tendon and surrounding tissue for RNA-grade needle capture or
histologic imaging
Materials:
- Scalpel holder + #11 scalpel blades
- Fine forceps
- Falcon tubes (10mL for P7, P14 mice, 50mL for P21 mice)
- 10X PBS, Nuclease-free (Invitrogen #AM9625)
- Water, Nuclease-free (Fisher #BP561-1)
- 32% PFA, EM grade (EMS, #15714-S)
- 2-Methylbutane
- Dry Ice
- Kimwipes
- OCT Embedding medium
- Embedding molds, 24 x 24 x 5mm
Procedure:
1. On day of harvest, prepare fresh PFA solution
a. For P7 and P14 mice, prepare 10mL by combining:
i. 1mL 10x PBS
ii. 7.75mL Water
iii. 1.25mL PFA (in hood)
b. For P21 mice, prepare 30mL by combining:
i. 3mL 10x PBS
ii. 23.25mL Water
iii. 3.75mL PFA (in hood)
2. Properly sacrifice mice
a. For <P14 mice, secondary confirmation (decapitation) required
3. Dissect hindlimbs with scalpel and forceps
a. Cut off limb at knee
b. Cut off toes, leaving big toe preserved for orientation during embedding
c. Slice skin down front of shin and foot
d. Deglove hindlimb
4. Place hindlimbs in PFA solution
a. Ensure ankle is flexed at ~90⁰
5. Incubate hindlimbs in solution for 3hr at 4⁰C
6. 15min prior to fixation timepoint, cool 2-methylbutane with dry ice
7. Embed hindlimbs
a. Dry off hindlimbs with Kimwipe
b. Coat bottom of embedding mold with OCT
c. Orient hindlimbs within mold
i. User preference, lateral side down
ii. Best for sectioning if calcaneus is pressed to mold bottom
d. Coat samples in OCT
8. Freeze embedded samples in 2-methylbutane
a. Only immerse mold bottom and allow bottom OCT layer to freeze
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b. Plunge rest of mold in 2-methylbutane, let freeze for at least 1min
9. Store at -80⁰C for future sectioning
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APPENDIX G: Hindlimb Cryosectioning (Histology)

Objective: Section frozen ankle samples for downstream histologic analysis
Materials:
- Cryostat + chuck
- Blades (Sturkey #D554X50 and #D554D50)
- Cryostat roller
- Brush
- CryoJane tape (via Histology Core)
- Fine forceps
- OCT embedding media
- Plastic slides
- Kimwipes
- Microscope (4x objective)
Procedure:
1. Precool blades, roller, brush, forcep, and samples, cut tape and cool
a. Turn on cryostat to -20⁰C and once equilibrated, cool supplies in hood for
~20min
b. While supplies are cooling, cut tape for cryosections
i. 1.25x the width of strip lines worked well
2. Trim sample block with blade to minimize excess OCT
3. Embed sample on chuck
a. Turn on cryobar and place chuck on cryobar
b. Squeeze glob of OCT on block, wait until center starts freezing
c. Embed sample in freezing OCT
i. With younger ages (P7), it is easiest to get FDL tendon alignment
with the bottom of the foot raised relative to the tibia.
ii. With older postnatal ages (P21), FDL tendon alignment is best
achieved when the tibia and foot are relatively in plane, parallel to
chuck surface
4. Mount sample and section through lateral hindlimb (Extremus blades,
30μm→20μm)
a. Periodically check alignment by collecting on plastic slide and viewing
with 4x objective microscope (see below for collecting sections)
b. Adjust as needed based on embedded sample alignment
c. When nearing FDL tendon, reduce section thickness to avoid wasting
sample
5. Collect sample sections (Diamond blades, 8μm)
a. Cleanest, most uniform sections are achieved when tibia is near parallel
to cut surface
b. When FDL tendon is reached, place tape on sample surface, with long
axis in same direction as the tibia, spanning the calcaneus through at
least the midfoot
c. Roll on tape with cryoroller to ensure adherence of tape to sample
d. While gripping gold tape with forceps, section through tissue. Sample will
glide onto blade stage, stuck to cryotape.
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e. Swipe cryosection onto plastic slide just outside the cryohood. The OCT
will melt and stick the section to the slide
i. 4-5 sections can be kept on one slide
f. Check sections with 4x objective to ensure alignment and to reduce
shredding
g. Repeat until FDL tendon has been fully collected
6. Transfer slides on ice to -20⁰C freezer for later gluing and staining
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APPENDIX H: Hindlimb Cryosectioning (Needle Capture Gene Expression)

Objective: Section frozen ankle samples for downstream needle capture tissue
dissection and gene analysis
Materials:
- Cryostat + chuck
- Blades (Sturkey #D554X50)
- Cryostat roller
- Brush
- CryoJane tape (via Histology Core)
- Fine forceps
- OCT embedding media
- Glass (and Plastic) slides
- Kimwipes
- Microscope (4x objective)
- Dry ice
Procedure:
1. Precool blades, roller, brush, forcep, glass slides, and samples, cut tape and cool
a. Turn on cryostat to -20⁰C and once equilibrated, cool supplies in hood for
~20min
b. While supplies are cooling, cut tape for cryosections
i. 1.25x the width of strip lines worked well
ii. For subsequent needle capture, more gold tape the better
2. Trim sample block with blade to minimize excess OCT
3. Embed sample on chuck
a. Turn on cryobar and place chuck on cryobar
b. Squeeze glob of OCT on block, wait until center starts freezing
c. Embed sample in freezing OCT
i. With younger ages (P7), it is easiest to get FDL tendon alignment
with the bottom of the foot raised relative to the tibia.
ii. With older postnatal ages (P21), FDL tendon alignment is best
achieved when the tibia and foot are relatively in plane, parallel to
chuck surface
4. Section through lateral hindlimb (30μm)
a. Periodically check alignment by collecting on plastic slide and viewing
with 4x objective microscope (see below for collecting sections)
b. Adjust as needed based on embedded sample alignment
5. Collect sample sections (20μm)
a. When FDL tendon is reached, place tape on sample surface, with long
axis in same direction as the tibia, spanning the calcaneus through at
least the midfoot
b. Roll on tape with cryoroller to ensure adherence of tape to sample
c. While gripping gold tape with forceps, section through tissue. Sample will
glide onto blade stage, stuck to cryotape.
d. Place cryosection face up on cooled glass slide
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i. If collecting on plastic slides, swipe cryosection onto plastic slide
just outside the cryohood. The OCT will melt and stick the section
to the slide
e. After three sections per slide, drizzle a line of OCT across glass slide and
gold tape to bind cryosections to slide upon freezing
i. Keep slides at -20⁰C or on dry ice
f. After 3-4 slides, periodically check to see if FDL tendon has been
sectioned through
g. Repeat until FDL tendon has been fully collected
6. Transfer slides on dry ice to -80⁰C freezer for future needle dissection
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APPENDIX I: Needle Capture Dissection (Gene Expression)
Objective: Dissect tensile and compressive FDL tendon regions from cryosections for
regional gene analysis
Materials:
- Dissection scope w/ backlight
- 70% Ethanol
- RNase Zap
- 25G needle tips (w/ syringe for grip)
- Fine forceps
- Scissors
- DI Water
- CryoJane tape (via Histology Core)
- Glass Slides
- Eppendorf tubes
- Dry ice
Procedure:
1. Keep slide samples on dry ice until actively dissected
2. Label Eppendorf tubes for each sample x region and cool on dry ice
3. Cut small pieces of cryotape for tissue capture
a. Edge of cryotape sheet is convenient length of adhesive portion
b. Place on slides sticky side up, distinguished for each region
4. Dissect regions from sample cryosections
a. Place slide on backlit microscope
b. As section OCT melts, identify FDL tendon regions
i. Tensile region: slightly distal from myotendinous junction and just
proximal of lower tibial notch
ii. Compressive region: begins at the medial malleolus and ends
distally beneath the sustenaculum tali
c. Cut tendon with sharp side of needle at each region border
d. Peel tendon region off tape with forceps
e. Transfer tissue sample onto tape on corresponding slide for the dissected
region
f. Repeat for other region and sections on slide
g. Transfer collected tissue to Eppendorf tube
i. Using forceps and scissors, cut region of tape that contains
collected tissue
h. Rinse needle, forceps, and scissors and spray with RNase Zap after each
section
i. Repeat for each sample until complete
5. Store Eppendorf samples in -80⁰C freezer
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APPENDIX J: RNA Extraction
Objective: RNA extraction from fixed, cryosectioned, dissected samples for subsequent
gene analysis
Materials:
- RNase Zap
- Pipettes (1000μL, 200μL, 20μL, 2μL) and associated tips
- Heated water bath
- Heat block
- Proteinase K (Zymo, #D3001-2-20)
- 2X Digest buffer (Zymo, #D3050-1-20)
- RNase/DNase free water
- Eppendorf tubes
- Quick-RNA Microprep kit (Zymo, #R1050)
- RNA-clean 100% ethanol
- Centrifuge (all listed spin steps at max speed)
- Vortexer
Procedure:
1. Warm up water bath to 55⁰C
2. Prepare proteinase K cocktail (200μL total per sample):
a. 95μL RNase/DNase free water
b. 95μL 2X Digest Buffer
c. 10μL Proteinase K
d. 1.1x for pipette offset
3. Add proteinase K cocktail to samples, ensuring that tissue samples are fully
immersed in liquid
4. Incubate samples in water bath for 1hr
a. With ~15min left, warm up heat block to 65⁰C
5. Incubate samples in heat block for 15min
a. Allocate and label Eppendorf tubes, spin columns, and collection tubes
(per sample):
i. 3-4 Eppendorf tubes (lysis wash, ethanol wash, eluted RNA, and
Bioanalyzer if necessary)
ii. 1 spin column
iii. 1 collection tube
b. Prepare DNase solution (per sample):
i. 35μL DNA Digestion Buffer
ii. 5μL DNase
iii. 1.1x for pipette offset
6. Spin down samples for ~30s and transfer solution (no tape) to new Eppendorf
tube
7. Add 200μL RNA lysis buffer and vortex to mix well
8. Centrifuge for ~1min and transfer supernatant to new Eppendorf tube
9. Add 400μL ethanol (1:1 sample volume) and vortex to mix well
10. Transfer sample to spin column in collection tube
11. Centrifuge for ~1min and discard flow-through
12. Add 400μL RNA Wash Buffer to spin column
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13. Centrifuge for ~1min and discard flow-through
14. Add 40μL DNase solution directly to spin column matrix, incubate for 15min
15. Add 400μL RNA Prep Buffer to spin column
16. Centrifuge for ~1min and discard flow-through
17. Add 700μL RNA Wash Buffer to spin column
18. Centrifuge for ~1min and discard flow-through
19. Add 400μL RNA Wash Buffer to spin column
20. Centrifuge for 2min (to ensure complete elution of ethanol washes) and transfer
spin column to Eppendorf tube
21. Add 15μL RNase/DNase Free Water to spin column
22. Centrifuge for ~1.5min to fully elute sample
23. Eluted RNA can be immediately tested on NanoDrop for concentration
24. If performing Bioanalyzer run later for RNA quality, allocate 3μL in separate
Eppendorf
25. Store at -80⁰C for subsequent cDNA synthesis and preamplification
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APPENDIX K: cDNA Synthesis and Preamplification
Objective: Convert template RNA samples to cDNA and preamplify for subsequent
Fluidigm Dynamic Array analysis
Materials:
- Pipettes (1000μL, 200 μL, 20 μL, 2μL) and associated tips
- High-Capacity cDNA Reverse Transcription kit (Thermo, #4368814)
- RNase/DNase free water
- 96 well plates
- Plastic plate sealers
- Thermal cycler
- Preamp master mix (Fluidigm, #100-5580)
- Taqman probes for target genes
- Dilution reagent (Fluidigm, #100-8726)
- Ice
Procedure:
1. Thaw cDNA RT kit reagents on ice
2. Prepare cDNA RT master mix (MM, per sample):
a. 2μL 10X RT Buffer
b. 0.8μL 25X dNTP Mix
c. 2μL 10X Random Primers
d. 1μL Reverse Transcriptase (not included in NoRT MM)
e. 4.2μL Nuclease-free water (for NoRT MM, becomes 5.2μL)
f. 1.1x offset for pipetting error
3. Pipette 10μL of MM into each plate well allocated for samples
a. Thaw RNA samples on ice during this step
4. Pipette 10μL of RNA sample into corresponding plate well
a. Pipette up and down to ensure well-mixed
b. If diluting RNA sample, add nuclease-free water to achieve 10μL (20μL
total)
5. Seal plate, and centrifuge if air bubbles are present
6. Perform cDNA synthesis via thermal cycler with following protocol:
a. 25⁰C for 10min
b. 37⁰C for 120min
c. 85⁰C for 5min
d. 4⁰C indefinitely
7. POTENTIAL STOP: Plate can be stored at -20⁰C indefinitely
8. Thaw preamp master mix and associated Taqman probes on ice
9. Prepare pooled assay mix:
a. Determine volume needed
i. 100μL minimum, or 1.25 x (# samples) x 1.1 (offset for pipetting
error)
b. Volume per Taqman probe: Total volume/100
c. Volume of dilution reagent: Total volume – volume of Taqman probes
10. Prepare preamp master mix (MM, per sample):
a. 1μL Preamp master mix
b. 1.25μL pooled assay mix
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c. 1.5μL nuclease-free water
11. Pipette 3.75μL of MM into each plate well allocated for samples
12. Pipette 1.25μL of cDNA sample into corresponding plate well
a. Pipette up and down to ensure well-mixed
13. Seal plate, and centrifuge if air bubbles are present
14. Perform preamplification via thermal cycler with following protocol:
a. 95⁰C for 2min
b. 95⁰C for 15sec
c. 60⁰C for 4min
d. Repeat b + c until appropriate number of cycles are reached
e. 4⁰C indefinitely
15. Add 20μL dilution reagent to each sample well
16. Reseal and store at -20⁰C
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APPENDIX L: Section Gluing and Collagen VI Immunostaining
Objective: Prepare cryosections for collagen VI immunofluorescence imaging with
section gluing, staining, and coverslipping
Materials:
- Pipettes (1000μL, 200 μL, 20 μL, 2μL) and associated tips
- Glass slides
- Chitosan in acetic acid
- Kimwipes
- Slide box
- Fine forceps
- Scissors
- Microscope (w/ 4x objective)
- Natural goat serum
- 1x PBS
- Slide wash bins
- Collagen VI primary antibody (Fitzgerald, #70R-CR009X)
- “Humidor” slide box
- Goat anti-rabbit secondary antibody, Alexa 647 (Thermo, #A-21245)
- 50% glycerol in 1x PBS
- Hoescht nuclear stain
- Coverslips
Procedure:
6. Select ~3 sections/sample to stain and image
7. Label glass slide and pipette ~60μL chitosan in a line spanning slide viewing
window
8. Trim candidate sections with scissors to remove gold tape, excessive cryotape
9. Wick bottom of section with chitosan, swipe onto glass slide
a. Check for air bubbles under microscope and repeat until bubbles
removed
10. Rest slides in slide box on Kimwipe
a. Ensure that sections do not fall down slide
b. Wick excess chitosan onto Kimwipe to ensure proper drying
11. Dry with slide box ajar, 1 day at RT, 1 day at 4⁰C
12. POTENTIAL STOP POINT: Store glued slides at -20⁰C indefinitely
13. Prepare 5% natural goat serum (NGS) in 1xPBS
a. ~1000μL/slide required
14. Prepare 1⁰ Ab solution
a. 1:50 dilution in 5% NGS, ~350μL/slide
15. Prepare “humidor slide box”
a. Wet Kimwipes with DI water, roll and place into humidor slide box slots
16. 1⁰ Ab stain (in humidor slide box)
a. 3 washes in 1x PBS (~20min each)
b. Block with 5% NGS (300μL/slide) for 20min at RT
c. 3 washes in 1x PBS (~20min each)
d. Stain with 1⁰ Ab solution (300μL/slide) overnight at 4⁰C
17. NEXT DAY: Aspirate off 1⁰ Ab solution
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18. Prepare 2⁰ Ab solution
a. 1:1000 dilution in 5% NGS, ~350μL/slide
19. 2⁰ Ab solution
a. 3 washes in 1x PBS (~20min each)
b. Stain with 2⁰ Ab solution (300μL/slide) for 1hr at RT
c. 3 washes in 1x PBS (~20min each)
20. Prepare Hoescht coverslip solution
a. 1:1000 dilution in 50% glycerol, ~300μL/slide
21. Aspirate off 2⁰ Ab solution
22. Coverslip
a. Pipette Hoescht coverslip solution onto sections
b. Place coverslip on slide by slowly dropping coverslip, starting with contact
at the bottom of the slide
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